{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:50:52Z","timestamp":1794649852743,"version":"4.9.1"},"reference-count":469,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004418","name":"Vrije Universiteit Brussel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004418","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004418","name":"Vrije Universiteit Brussel","doi-asserted-by":"publisher","award":["SRP84"],"award-info":[{"award-number":["SRP84"]}],"id":[{"id":"10.13039\/501100004418","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kom op Tegen Kanker BE"},{"name":"FWO Vlaanderen"},{"name":"Kom op Tegen kanker & FWO Vlaanderen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02923-x","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:01:40Z","timestamp":1788390100000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["T cell senescence and exhaustion: molecular mechanisms and immune rejuvenation for cancer immunotherapy"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0158-4630","authenticated-orcid":false,"given":"Lauren","family":"van den Broecke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0345-721X","authenticated-orcid":false,"given":"Arne","family":"Van der Vreken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenja","family":"Watt\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fien","family":"Meeus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"De Veirman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Breckpot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4012-4617","authenticated-orcid":false,"given":"Elke","family":"De Bruyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0805-6581","authenticated-orcid":false,"given":"Eline","family":"Menu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"2923_CR1","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nature22395","volume":"545","author":"M Sadelain","year":"2017","unstructured":"Sadelain, M., Rivi\u00e8re, I. & Riddell, S. Therapeutic T cell engineering. Nature 545, 423\u2013431 (2017).","journal-title":"Nature"},{"key":"2923_CR2","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651\u2013668 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"2923_CR3","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.immuni.2018.01.007","volume":"48","author":"BV Kumar","year":"2018","unstructured":"Kumar, B. V., Connors, T. J. & Farber, D. L. Human T Cell Development, Localization, and Function throughout Life. Immunity 48, 202\u2013213 (2018).","journal-title":"Immunity"},{"key":"2923_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1146\/annurev-immunol-090222-110914","volume":"42","author":"A Baessler","year":"2024","unstructured":"Baessler, A. & Vignali, D. A. A. T Cell Exhaustion. Annu. Rev. Immunol. 42, 179\u2013206 (2024).","journal-title":"Annu. Rev. Immunol."},{"key":"2923_CR5","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15, 486\u2013499 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"2923_CR6","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41392-023-01451-2","volume":"8","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. Immunosenescence: molecular mechanisms and diseases. Signal Transduct. Target Ther. 8, 200 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2923_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41590-021-00927-z","volume":"22","author":"M Mittelbrunn","year":"2021","unstructured":"Mittelbrunn, M. & Kroemer, G. Hallmarks of T cell aging. Nat. Immunol. 22, 687\u2013698 (2021).","journal-title":"Nat. Immunol."},{"key":"2923_CR8","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41590-024-01828-7","volume":"25","author":"ACY Chen","year":"2024","unstructured":"Chen, A. C. Y. et al. The aged tumor microenvironment limits T cell control of cancer. Nat. Immunol. 25, 1033\u20131045 (2024).","journal-title":"Nat. Immunol."},{"key":"2923_CR9","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.ccell.2024.08.007","volume":"42","author":"K Wang","year":"2024","unstructured":"Wang, K. et al. Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells. Cancer Cell 42, 1582\u20131597.e1510 (2024).","journal-title":"Cancer Cell"},{"key":"2923_CR10","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1038\/s41591-023-02498-y","volume":"29","author":"A VanderWalde","year":"2023","unstructured":"VanderWalde, A. et al. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat. Med. 29, 2278\u20132285 (2023).","journal-title":"Nat. Med."},{"key":"2923_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","volume":"14","author":"Z Tian","year":"2021","unstructured":"Tian, Z., Liu, M., Zhang, Y. & Wang, X. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J. Hematol. Oncol. 14, 75 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"2923_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/CCO.0000000000000925","volume":"35","author":"L Tas","year":"2023","unstructured":"Tas, L., Jedema, I. & Haanen, J. B. A. G. Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes (TILs) for patients with solid cancers. Curr. Opin. Oncol. 35, 107\u2013113 (2023).","journal-title":"Curr. Opin. Oncol."},{"key":"2923_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13045-021-01115-0","volume":"14","author":"AM Tsimberidou","year":"2021","unstructured":"Tsimberidou, A. M. et al. T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors. J. Hematol. Oncol. 14, 102 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"2923_CR14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June, C. H. & Sadelain, M. Chimeric Antigen Receptor Therapy. N. Engl. J. Med. 379, 64\u201373 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2923_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/acel.14300","volume":"23","author":"H Slaets","year":"2024","unstructured":"Slaets, H. et al. Are immunosenescent T cells really senescent? Aging Cell 23, e14300 (2024).","journal-title":"Aging Cell"},{"key":"2923_CR16","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0092-8674(00)80453-5","volume":"91","author":"M Kondo","year":"1997","unstructured":"Kondo, M., Weissman, I. L. & Akashi, K. Identification of clonogenic common lymphoid progenitors in mouse bone marrow. Cell 91, 661\u2013672 (1997).","journal-title":"Cell"},{"key":"2923_CR17","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1182\/blood-2008-04-150508","volume":"112","author":"CT Jensen","year":"2008","unstructured":"Jensen, C. T. et al. FLT3 ligand and not TSLP is the key regulator of IL-7-independent B-1 and B-2 B lymphopoiesis. Blood 112, 2297\u20132304 (2008).","journal-title":"Blood"},{"key":"2923_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-0716-2740-2_1","volume":"2580","author":"R Bosselut","year":"2023","unstructured":"Bosselut, R. A Beginner\u2019s Guide to T Cell Development. Methods Mol. Biol. 2580, 3\u201324 (2023).","journal-title":"Methods Mol. Biol."},{"key":"2923_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/978-3-031-77921-3_5","volume":"1471","author":"DA Mendes-da-Cruz","year":"2025","unstructured":"Mendes-da-Cruz, D. A., Lemos, J. P., Belorio, E. P. & Savino, W. Intrathymic Cell Migration: Implications in Thymocyte Development and T Lymphocyte Repertoire Formation. Adv. Exp. Med. Biol. 1471, 139\u2013175 (2025).","journal-title":"Adv. Exp. Med. Biol."},{"key":"2923_CR20","doi-asserted-by":"publisher","first-page":"52487","DOI":"10.1074\/jbc.M406512200","volume":"279","author":"ML Allende","year":"2004","unstructured":"Allende, M. L. et al. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J. Biol. Chem. 279, 52487\u201352492 (2004).","journal-title":"J. Biol. Chem."},{"key":"2923_CR21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/imr.12758","volume":"289","author":"B Le\u00f3n","year":"2019","unstructured":"Le\u00f3n, B. & Lund, F. E. Compartmentalization of dendritic cell and T-cell interactions in the lymph node: Anatomy of T-cell fate decisions. Immunol. Rev. 289, 84\u2013100 (2019).","journal-title":"Immunol. Rev."},{"key":"2923_CR22","doi-asserted-by":"publisher","DOI":"10.4110\/in.2023.23.e4","volume":"23","author":"GR Lee","year":"2023","unstructured":"Lee, G. R. Molecular Mechanisms of T Helper Cell Differentiation and Functional Specialization. Immune Netw. 23, e4 (2023).","journal-title":"Immune Netw."},{"key":"2923_CR23","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/(SICI)1521-4141(199903)29:03<838::AID-IMMU838>3.0.CO;2-P","volume":"29","author":"JH Fraser","year":"1999","unstructured":"Fraser, J. H., Rinc\u00f3n, M., McCoy, K. D. & Le Gros, G. CTLA4 ligation attenuates AP-1, NFAT and NF-kappaB activity in activated T cells. Eur. J. Immunol. 29, 838\u2013844 (1999).","journal-title":"Eur. J. Immunol."},{"key":"2923_CR24","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.cell.2012.09.044","volume":"151","author":"G Vahedi","year":"2012","unstructured":"Vahedi, G. et al. STATs shape the active enhancer landscape of T cell populations. Cell 151, 981\u2013993 (2012).","journal-title":"Cell"},{"key":"2923_CR25","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.tibs.2017.11.008","volume":"43","author":"AH Courtney","year":"2018","unstructured":"Courtney, A. H., Lo, W. L. & Weiss, A. TCR Signaling: Mechanisms of Initiation and Propagation. Trends Biochem. Sci. 43, 108\u2013123 (2018).","journal-title":"Trends Biochem. Sci."},{"key":"2923_CR26","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-018-0020-8","volume":"18","author":"G Gaud","year":"2018","unstructured":"Gaud, G., Lesourne, R. & Love, P. E. Regulatory mechanisms in T cell receptor signalling. Nat. Rev. Immunol. 18, 485\u2013497 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"2923_CR27","unstructured":"Pen, J. J. et al. in Immune Activation Response, Ch. 3 (Intech Open, 2014)."},{"key":"2923_CR28","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s002510000212","volume":"51","author":"P Shier","year":"2000","unstructured":"Shier, P. et al. Tbt-1, a new T-box transcription factor induced in activated Th1 and CD8+ T cells. Immunogenetics 51, 771\u2013778 (2000).","journal-title":"Immunogenetics"},{"key":"2923_CR29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4049\/jimmunol.173.1.68","volume":"173","author":"T Chtanova","year":"2004","unstructured":"Chtanova, T. et al. T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1\/Th2 effector cells that provide help for B cells. J. Immunol. 173, 68\u201378 (2004).","journal-title":"J. Immunol."},{"key":"2923_CR30","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","volume":"126","author":"II Ivanov","year":"2006","unstructured":"Ivanov, I. I. et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126, 1121\u20131133 (2006).","journal-title":"Cell"},{"key":"2923_CR31","doi-asserted-by":"crossref","unstructured":"Lai, L. et al. Cytotoxic CD4+ T cells: origin, biological functions, diseases and therapeutic targets. Signal Transduct Target Ther. 11, 85 (2026).","DOI":"10.1038\/s41392-025-02533-z"},{"key":"2923_CR32","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.immuni.2013.10.007","volume":"39","author":"S Yao","year":"2013","unstructured":"Yao, S. et al. Interferon regulatory factor 4 sustains CD8(+) T cell expansion and effector differentiation. Immunity 39, 833\u2013845 (2013).","journal-title":"Immunity"},{"key":"2923_CR33","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ni.2834","volume":"15","author":"M Kurachi","year":"2014","unstructured":"Kurachi, M. et al. The transcription factor BATF operates as an essential differentiation checkpoint in early effector CD8+ T cells. Nat. Immunol. 15, 373\u2013383 (2014).","journal-title":"Nat. Immunol."},{"key":"2923_CR34","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/j.cell.2024.03.037","volume":"187","author":"H Chi","year":"2024","unstructured":"Chi, H., Pepper, M. & Thomas, P. G. Principles and therapeutic applications of adaptive immunity. Cell 187, 2052\u20132078 (2024).","journal-title":"Cell"},{"key":"2923_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1\u201310 (2013).","journal-title":"Immunity"},{"key":"2923_CR36","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1016\/j.scib.2025.03.054","volume":"70","author":"K Ma","year":"2025","unstructured":"Ma, K. et al. T cell-based cancer immunotherapy: opportunities and challenges. Sci. Bull. 70, 1872\u20131890 (2025).","journal-title":"Sci. Bull."},{"key":"2923_CR37","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41577-024-01040-6","volume":"24","author":"N Lam","year":"2024","unstructured":"Lam, N., Lee, Y. & Farber, D. L. A guide to adaptive immune memory. Nat. Rev. Immunol. 24, 810\u2013829 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"2923_CR38","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/44385","volume":"401","author":"F Sallusto","year":"1999","unstructured":"Sallusto, F. et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401, 708\u2013712 (1999).","journal-title":"Nature"},{"key":"2923_CR39","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1099\/vir.0.036004-0","volume":"92","author":"E Derhovanessian","year":"2011","unstructured":"Derhovanessian, E. et al. Infection with cytomegalovirus but not herpes simplex virus induces the accumulation of late-differentiated CD4+ and CD8+ T-cells in humans. J. Gen. Virol. 92, 2746\u20132756 (2011).","journal-title":"J. Gen. Virol."},{"key":"2923_CR40","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1084\/jem.20160758","volume":"214","author":"CL Gordon","year":"2017","unstructured":"Gordon, C. L. et al. Tissue reservoirs of antiviral T cell immunity in persistent human CMV infection. J. Exp. Med. 214, 651\u2013667 (2017).","journal-title":"J. Exp. Med."},{"key":"2923_CR41","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/nm.2446","volume":"17","author":"L Gattinoni","year":"2011","unstructured":"Gattinoni, L. et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 17, 1290\u20131297 (2011).","journal-title":"Nat. Med."},{"key":"2923_CR42","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.immuni.2023.02.010","volume":"56","author":"KC Osum","year":"2023","unstructured":"Osum, K. C. & Jenkins, M. K. Toward a general model of CD4+ T cell subset specification and memory cell formation. Immunity 56, 475\u2013484 (2023).","journal-title":"Immunity"},{"key":"2923_CR43","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/imcb.12272","volume":"97","author":"MS Soon","year":"2019","unstructured":"Soon, M. S., Engel, J. A., Lee, H. J. & Haque, A. Development of circulating CD4+ T cell memory. Immunol. Cell Biol. 97, 617\u2013624 (2019).","journal-title":"Immunol. Cell Biol."},{"key":"2923_CR44","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1146\/annurev-immunol-032414-112014","volume":"34","author":"VR Buchholz","year":"2016","unstructured":"Buchholz, V. R., Schumacher, T. N. & Busch, D. H. T Cell Fate at the Single-Cell Level. Annu. Rev. Immunol. 34, 65\u201392 (2016).","journal-title":"Annu. Rev. Immunol."},{"key":"2923_CR45","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.coi.2012.12.003","volume":"25","author":"J Crespo","year":"2013","unstructured":"Crespo, J. et al. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr. Opin. Immunol. 25, 214\u2013221 (2013).","journal-title":"Curr. Opin. Immunol."},{"key":"2923_CR46","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41577-020-00454-2","volume":"21","author":"MA ElTanbouly","year":"2021","unstructured":"ElTanbouly, M. A. & Noelle, R. J. Rethinking peripheral T cell tolerance: checkpoints across a T cell\u2019s journey. Nat. Rev. Immunol. 21, 257\u2013267 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"2923_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11075","volume":"7","author":"A Grover","year":"2016","unstructured":"Grover, A. et al. Single-cell RNA sequencing reveals molecular and functional platelet bias of aged haematopoietic stem cells. Nat. Commun. 7, 11075 (2016).","journal-title":"Nat. Commun."},{"key":"2923_CR48","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1101\/gr.192237.115","volume":"25","author":"MS Kowalczyk","year":"2015","unstructured":"Kowalczyk, M. S. et al. Single-cell RNA-seq reveals changes in cell cycle and differentiation programs upon aging of hematopoietic stem cells. Genome Res. 25, 1860\u20131872 (2015).","journal-title":"Genome Res."},{"key":"2923_CR49","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nri2959","volume":"11","author":"AN Akbar","year":"2011","unstructured":"Akbar, A. N. & Henson, S. M. Are senescence and exhaustion intertwined or unrelated processes that compromise immunity? Nat. Rev. Immunol. 11, 289\u2013295 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"2923_CR50","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41590-017-0006-x","volume":"19","author":"J Nikolich-\u017dugich","year":"2018","unstructured":"Nikolich-\u017dugich, J. The twilight of immunity: emerging concepts in aging of the immune system. Nat. Immunol. 19, 10\u201319 (2018).","journal-title":"Nat. Immunol."},{"key":"2923_CR51","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.bbi.2007.11.002","volume":"22","author":"RJ Simpson","year":"2008","unstructured":"Simpson, R. J. et al. Senescent T-lymphocytes are mobilised into the peripheral blood compartment in young and older humans after exhaustive exercise. Brain Behav. Immun. 22, 544\u2013551 (2008).","journal-title":"Brain Behav. Immun."},{"key":"2923_CR52","first-page":"1680","volume":"19","author":"JP Chou","year":"2013","unstructured":"Chou, J. P. & Effros, R. B. T cell replicative senescence in human aging. Curr. Pharm. Des. 19, 1680\u20131698 (2013).","journal-title":"Curr. Pharm. Des."},{"key":"2923_CR53","doi-asserted-by":"publisher","first-page":"7710","DOI":"10.4049\/jimmunol.178.12.7710","volume":"178","author":"FJ Plunkett","year":"2007","unstructured":"Plunkett, F. J. et al. The loss of telomerase activity in highly differentiated CD8+CD28-CD27- T cells is associated with decreased Akt (Ser473) phosphorylation. J. Immunol. 178, 7710\u20137719 (2007).","journal-title":"J. Immunol."},{"key":"2923_CR54","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/s41580-024-00727-x","volume":"25","author":"B Wang","year":"2024","unstructured":"Wang, B., Han, J., Elisseeff, J. H. & Demaria, M. The senescence-associated secretory phenotype and its physiological and pathological implications. Nat. Rev. Mol. Cell Biol. 25, 958\u2013978 (2024).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2923_CR55","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0092-8674(00)81902-9","volume":"88","author":"M Serrano","year":"1997","unstructured":"Serrano, M. et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593\u2013602 (1997).","journal-title":"Cell"},{"key":"2923_CR56","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1158\/2159-8290.CD-16-0241","volume":"7","author":"M Demaria","year":"2017","unstructured":"Demaria, M. et al. Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse. Cancer Discov. 7, 165\u2013176 (2017).","journal-title":"Cancer Discov."},{"key":"2923_CR57","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.cmet.2015.11.011","volume":"23","author":"CD Wiley","year":"2016","unstructured":"Wiley, C. D. et al. Mitochondrial Dysfunction Induces Senescence with a Distinct Secretory Phenotype. Cell Metab. 23, 303\u2013314 (2016).","journal-title":"Cell Metab."},{"key":"2923_CR58","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/nri3740","volume":"14","author":"DE Speiser","year":"2014","unstructured":"Speiser, D. E. et al. T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? Nat. Rev. Immunol. 14, 768\u2013774 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"2923_CR59","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/imr.13206","volume":"316","author":"P Laphanuwat","year":"2023","unstructured":"Laphanuwat, P., Gomes, D. C. O. & Akbar, A. N. Senescent T cells: Beneficial and detrimental roles. Immunol. Rev. 316, 160\u2013175 (2023).","journal-title":"Immunol. Rev."},{"key":"2923_CR60","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.coi.2005.07.019","volume":"17","author":"AN Akbar","year":"2005","unstructured":"Akbar, A. N. & Fletcher, J. M. Memory T cell homeostasis and senescence during aging. Curr. Opin. Immunol. 17, 480\u2013485 (2005).","journal-title":"Curr. Opin. Immunol."},{"key":"2923_CR61","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.3389\/fimmu.2018.01400","volume":"9","author":"N Teteloshvili","year":"2018","unstructured":"Teteloshvili, N. et al. Involvement of MicroRNAs in the Aging-Related Decline of CD28 Expression by Human T Cells. Front. Immunol. 9, 1400 (2018).","journal-title":"Front. Immunol."},{"key":"2923_CR62","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1474-9726.2012.00819.x","volume":"11","author":"S Brunner","year":"2012","unstructured":"Brunner, S. et al. Upregulation of miR-24 is associated with a decreased DNA damage response upon etoposide treatment in highly differentiated CD8(+) T cells sensitizing them to apoptotic cell death. Aging Cell 11, 579\u2013587 (2012).","journal-title":"Aging Cell"},{"key":"2923_CR63","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cyto.2019.01.013","volume":"117","author":"S Lopes-Paciencia","year":"2019","unstructured":"Lopes-Paciencia, S. et al. The senescence-associated secretory phenotype and its regulation. Cytokine 117, 15\u201322 (2019).","journal-title":"Cytokine"},{"key":"2923_CR64","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13067","volume":"19","author":"LA Callender","year":"2020","unstructured":"Callender, L. A. et al. Mitochondrial mass governs the extent of human T cell senescence. Aging Cell 19, e13067 (2020).","journal-title":"Aging Cell"},{"key":"2923_CR65","doi-asserted-by":"crossref","unstructured":"Rausser, S. et al. Mitochondrial phenotypes in purified human immune cell subtypes and cell mixtures. Elife. 10, e70899 (2021).","DOI":"10.7554\/eLife.70899"},{"key":"2923_CR66","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.cmet.2024.03.009","volume":"36","author":"W Tao","year":"2024","unstructured":"Tao, W., Yu, Z. & Han, J. J. Single-cell senescence identification reveals senescence heterogeneity, trajectory, and modulators. Cell Metab. 36, 1126\u20131143.e1125 (2024).","journal-title":"Cell Metab."},{"key":"2923_CR67","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1146\/annurev.immunol.22.012703.104702","volume":"22","author":"F Sallusto","year":"2004","unstructured":"Sallusto, F., Geginat, J. & Lanzavecchia, A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22, 745\u2013763 (2004).","journal-title":"Annu. Rev. Immunol."},{"key":"2923_CR68","doi-asserted-by":"crossref","unstructured":"Callender, L. A. et al. Human CD8+ EMRA T cells display a senescence-associated secretory phenotype regulated by p38 MAPK. Aging Cell. 17, e12675 (2018).","DOI":"10.1111\/acel.12675"},{"key":"2923_CR69","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1002\/eji.201445312","volume":"45","author":"SM Henson","year":"2015","unstructured":"Henson, S. M. et al. Blockade of PD-1 or p38 MAP kinase signaling enhances senescent human CD8(+) T-cell proliferation by distinct pathways. Eur. J. Immunol. 45, 1441\u20131451 (2015).","journal-title":"Eur. J. Immunol."},{"key":"2923_CR70","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1182\/blood-2002-07-2103","volume":"101","author":"JM Brenchley","year":"2003","unstructured":"Brenchley, J. M. et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 101, 2711\u20132720 (2003).","journal-title":"Blood"},{"key":"2923_CR71","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41392-025-02327-3","volume":"11","author":"Y Wu","year":"2026","unstructured":"Wu, Y. et al. Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion. Signal Transduct. Target Ther. 11, 2 (2026).","journal-title":"Signal Transduct. Target Ther."},{"key":"2923_CR72","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1126\/science.aae0491","volume":"354","author":"DR Sen","year":"2016","unstructured":"Sen, D. R. et al. The epigenetic landscape of T cell exhaustion. Science 354, 1165\u20131169 (2016).","journal-title":"Science"},{"key":"2923_CR73","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","volume":"12","author":"EJ Wherry","year":"2011","unstructured":"Wherry, E. J. T cell exhaustion. Nat. Immunol. 12, 492\u2013499 (2011).","journal-title":"Nat. Immunol."},{"key":"2923_CR74","doi-asserted-by":"publisher","first-page":"4911","DOI":"10.1128\/JVI.77.8.4911-4927.2003","volume":"77","author":"EJ Wherry","year":"2003","unstructured":"Wherry, E. J. et al. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77, 4911\u20134927 (2003).","journal-title":"J. Virol."},{"key":"2923_CR75","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1084\/jem.20150598","volume":"213","author":"DT Utzschneider","year":"2016","unstructured":"Utzschneider, D. T. et al. High antigen levels induce an exhausted phenotype in a chronic infection without impairing T cell expansion and survival. J. Exp. Med. 213, 1819\u20131834 (2016).","journal-title":"J. Exp. Med."},{"key":"2923_CR76","doi-asserted-by":"publisher","first-page":"15016","DOI":"10.1073\/pnas.0801497105","volume":"105","author":"SD Blackburn","year":"2008","unstructured":"Blackburn, S. D., Shin, H., Freeman, G. J. & Wherry, E. J. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc. Natl. Acad. Sci. USA 105, 15016\u201315021 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2923_CR77","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41577-019-0223-7","volume":"20","author":"A Kallies","year":"2020","unstructured":"Kallies, A., Zehn, D. & Utzschneider, D. T. Precursor exhausted T cells: key to successful immunotherapy? Nat. Rev. Immunol. 20, 128\u2013136 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"2923_CR78","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1002\/eji.201242852","volume":"42","author":"EI Zuniga","year":"2012","unstructured":"Zuniga, E. I. & Harker, J. A. T-cell exhaustion due to persistent antigen: quantity not quality? Eur. J. Immunol. 42, 2285\u20132289 (2012).","journal-title":"Eur. J. Immunol."},{"key":"2923_CR79","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","volume":"52","author":"JC Beltra","year":"2020","unstructured":"Beltra, J. C. et al. Developmental Relationships of Four Exhausted CD8(+) T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. Immunity 52, 825\u2013841.e828 (2020).","journal-title":"Immunity"},{"key":"2923_CR80","doi-asserted-by":"publisher","first-page":"6081","DOI":"10.1016\/j.cell.2021.11.016","volume":"184","author":"CR Good","year":"2021","unstructured":"Good, C. R. et al. An NK-like CAR T cell transition in CAR T cell dysfunction. Cell 184, 6081\u20136100.e6026 (2021).","journal-title":"Cell"},{"key":"2923_CR81","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1038\/s41590-022-01337-5","volume":"23","author":"B Daniel","year":"2022","unstructured":"Daniel, B. et al. Divergent clonal differentiation trajectories of T cell exhaustion. Nat. Immunol. 23, 1614\u20131627 (2022).","journal-title":"Nat. Immunol."},{"key":"2923_CR82","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","volume":"571","author":"O Khan","year":"2019","unstructured":"Khan, O. et al. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature 571, 211\u2013218 (2019).","journal-title":"Nature"},{"key":"2923_CR83","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41586-019-0979-8","volume":"567","author":"X Liu","year":"2019","unstructured":"Liu, X. et al. Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction. Nature 567, 525\u2013529 (2019).","journal-title":"Nature"},{"key":"2923_CR84","doi-asserted-by":"publisher","first-page":"600829","DOI":"10.3389\/fimmu.2021.600829","volume":"12","author":"SD Gunasinghe","year":"2021","unstructured":"Gunasinghe, S. D., Peres, N. G., Goyette, J. & Gaus, K. Biomechanics of T Cell Dysfunctions in Chronic Diseases. Front. Immunol. 12, 600829 (2021).","journal-title":"Front. Immunol."},{"key":"2923_CR85","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41423-019-0344-8","volume":"17","author":"Y Zhao","year":"2020","unstructured":"Zhao, Y., Shao, Q. & Peng, G. Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment. Cell Mol. Immunol. 17, 27\u201335 (2020).","journal-title":"Cell Mol. Immunol."},{"key":"2923_CR86","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/ni.2981","volume":"15","author":"A Lanna","year":"2014","unstructured":"Lanna, A., Henson, S. M., Escors, D. & Akbar, A. N. The kinase p38 activated by the metabolic regulator AMPK and scaffold TAB1 drives the senescence of human T cells. Nat. Immunol. 15, 965\u2013972 (2014).","journal-title":"Nat. Immunol."},{"key":"2923_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.638010","volume":"12","author":"CL Shive","year":"2021","unstructured":"Shive, C. L. et al. Markers of T Cell Exhaustion and Senescence and Their Relationship to Plasma TGF-\u03b2 Levels in Treated HIV+ Immune Non-responders. Front. Immunol. 12, 638010 (2021).","journal-title":"Front. Immunol."},{"key":"2923_CR88","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-018-0629-x","volume":"11","author":"D Kasakovski","year":"2018","unstructured":"Kasakovski, D., Xu, L. & Li, Y. T cell senescence and CAR-T cell exhaustion in hematological malignancies. J. Hematol. Oncol. 11, 91 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"2923_CR89","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","volume":"4","author":"DJ Chung","year":"2016","unstructured":"Chung, D. J. et al. T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy. Cancer Immunol. Res. 4, 61\u201371 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"2923_CR90","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12929-018-0422-8","volume":"25","author":"R Le\u00e3o","year":"2018","unstructured":"Le\u00e3o, R. et al. Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer. J. Biomed. Sci. 25, 22 (2018).","journal-title":"J. Biomed. Sci."},{"key":"2923_CR91","doi-asserted-by":"publisher","first-page":"103989","DOI":"10.1016\/j.cellimm.2019.103989","volume":"345","author":"M Patrick","year":"2019","unstructured":"Patrick, M. & Weng, N. P. Expression and regulation of telomerase in human T cell differentiation, activation, aging and diseases. Cell Immunol. 345, 103989 (2019).","journal-title":"Cell Immunol."},{"key":"2923_CR92","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12979-022-00273-0","volume":"19","author":"DM Matthe","year":"2022","unstructured":"Matthe, D. M. et al. Telomerase deficiency reflects age-associated changes in CD4+ T cells. Immun. Ageing 19, 16 (2022).","journal-title":"Immun. Ageing"},{"key":"2923_CR93","doi-asserted-by":"crossref","unstructured":"Nguyen, L. N. T. et al. TRF2 inhibition rather than telomerase disruption drives CD4T cell dysfunction during chronic viral infection. J Cell Sci. 135, jcs259481 (2022).","DOI":"10.1242\/jcs.259481"},{"key":"2923_CR94","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cellimm.2014.03.009","volume":"289","author":"Y Qian","year":"2014","unstructured":"Qian, Y., Yang, L. & Cao, S. Telomeres and telomerase in T cells of tumor immunity. Cell Immunol. 289, 63\u201369 (2014).","journal-title":"Cell Immunol."},{"key":"2923_CR95","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/s41556-022-00991-z","volume":"24","author":"A Lanna","year":"2022","unstructured":"Lanna, A. et al. An intercellular transfer of telomeres rescues T cells from senescence and promotes long-term immunological memory. Nat. Cell Biol. 24, 1461\u20131474 (2022).","journal-title":"Nat. Cell Biol."},{"key":"2923_CR96","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/nri890","volume":"2","author":"RJ Hodes","year":"2002","unstructured":"Hodes, R. J., Hathcock, K. S. & Weng, N. P. Telomeres in T and B cells. Nat. Rev. Immunol. 2, 699\u2013706 (2002).","journal-title":"Nat. Rev. Immunol."},{"key":"2923_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10522-018-9769-1","volume":"20","author":"Y Zhu","year":"2019","unstructured":"Zhu, Y. et al. Telomere and its role in the aging pathways: telomere shortening, cell senescence and mitochondria dysfunction. Biogerontology 20, 1\u201316 (2019).","journal-title":"Biogerontology"},{"key":"2923_CR98","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1172\/JCI75051","volume":"124","author":"SM Henson","year":"2014","unstructured":"Henson, S. M. et al. p38 signaling inhibits mTORC1-independent autophagy in senescent human CD8\u207a T cells. J. Clin. Invest 124, 4004\u20134016 (2014).","journal-title":"J. Clin. Invest"},{"key":"2923_CR99","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nature02118","volume":"426","author":"F d'Adda di Fagagna","year":"2003","unstructured":"d'Adda di Fagagna, F. et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 426, 194\u2013198 (2003).","journal-title":"Nature"},{"key":"2923_CR100","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S1097-2765(04)00256-4","volume":"14","author":"U Herbig","year":"2004","unstructured":"Herbig, U. et al. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol. Cell 14, 501\u2013513 (2004).","journal-title":"Mol. Cell"},{"key":"2923_CR101","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nature09787","volume":"470","author":"E Sahin","year":"2011","unstructured":"Sahin, E. et al. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 470, 359\u2013365 (2011).","journal-title":"Nature"},{"key":"2923_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.698565","volume":"12","author":"V Janelle","year":"2021","unstructured":"Janelle, V. et al. p16(INK4a) Regulates Cellular Senescence in PD-1-Expressing Human T Cells. Front. Immunol. 12, 698565 (2021).","journal-title":"Front. Immunol."},{"key":"2923_CR103","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0952-7915(00)00224-7","volume":"13","author":"M Rinc\u00f3n","year":"2001","unstructured":"Rinc\u00f3n, M. MAP-kinase signaling pathways in T cells. Curr. Opin. Immunol. 13, 339\u2013345 (2001).","journal-title":"Curr. Opin. Immunol."},{"key":"2923_CR104","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0531-5565(98)00061-8","volume":"34","author":"T F\u00fcl\u00f6p","year":"1999","unstructured":"F\u00fcl\u00f6p, T. et al. Age-related impairment of p56lck and ZAP-70 activities in human T lymphocytes activated through the TcR\/CD3 complex. Exp. Gerontol. 34, 197\u2013216 (1999).","journal-title":"Exp. Gerontol."},{"key":"2923_CR105","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/ni.3665","volume":"18","author":"A Lanna","year":"2017","unstructured":"Lanna, A. et al. A sestrin-dependent Erk-Jnk-p38 MAPK activation complex inhibits immunity during aging. Nat. Immunol. 18, 354\u2013363 (2017).","journal-title":"Nat. Immunol."},{"key":"2923_CR106","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1503018","volume":"15","author":"K Raychaudhuri","year":"2024","unstructured":"Raychaudhuri, K. et al. CD28 shapes T cell receptor signaling by regulating Lck dynamics and ZAP70 activation. Front. Immunol. 15, 1503018 (2024).","journal-title":"Front. Immunol."},{"key":"2923_CR107","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41590-020-0643-3","volume":"21","author":"BI Pereira","year":"2020","unstructured":"Pereira, B. I. et al. Sestrins induce natural killer function in senescent-like CD8(+) T cells. Nat. Immunol. 21, 684\u2013694 (2020).","journal-title":"Nat. Immunol."},{"key":"2923_CR108","doi-asserted-by":"publisher","first-page":"e13668","DOI":"10.1111\/acel.13668","volume":"21","author":"D Z\u00f6phel","year":"2022","unstructured":"Z\u00f6phel, D. et al. Faster cytotoxicity with age: Increased perforin and granzyme levels in cytotoxic CD8+ boost cancer cell elimination. Aging Cell 21, e13668 (2022).","journal-title":"Aging Cell"},{"key":"2923_CR109","doi-asserted-by":"crossref","unstructured":"Dahlquist, K. J. V. et al. In vivo labeling reveals that degranulation is increased under supraphysiological TCR stimulation, but not infection, in CD8+ T cells from old mice. Geroscience 48, 897\u2013913 (2025).","DOI":"10.1007\/s11357-025-01723-5"},{"key":"2923_CR110","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13824","volume":"22","author":"D Z\u00f6phel","year":"2023","unstructured":"Z\u00f6phel, D. et al. Heterozygous OT-I mice reveal that antigen-specific CD8+ T cells shift from apoptotic to necrotic killers in the elderly. Aging Cell 22, e13824 (2023).","journal-title":"Aging Cell"},{"key":"2923_CR111","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1093\/gerona\/glx020","volume":"72","author":"Y Raz","year":"2017","unstructured":"Raz, Y. et al. Activation-Induced Autophagy Is Preserved in CD4+ T-Cells in Familial Longevity. J. Gerontol. A Biol. Sci. Med. Sci. 72, 1201\u20131206 (2017).","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"2923_CR112","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2322929121","volume":"121","author":"CA Reynolds","year":"2024","unstructured":"Reynolds, C. A. et al. Restoration of LAMP2A expression in old mice leads to changes in the T cell compartment that support improved immune function. Proc. Natl. Acad. Sci. USA 121, e2322929121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2923_CR113","doi-asserted-by":"publisher","first-page":"9363","DOI":"10.1073\/pnas.92.20.9363","volume":"92","author":"GP Dimri","year":"1995","unstructured":"Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 92, 9363\u20139367 (1995).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2923_CR114","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1474-9726.2006.00199.x","volume":"5","author":"BY Lee","year":"2006","unstructured":"Lee, B. Y. et al. Senescence-associated beta-galactosidase is lysosomal beta-galactosidase. Aging Cell 5, 187\u2013195 (2006).","journal-title":"Aging Cell"},{"key":"2923_CR115","doi-asserted-by":"crossref","unstructured":"Turano, P. S. et al. Epigenetic mechanisms regulating CD8+ T cell senescence in aging humans. bioRxiv https:\/\/www.biorxiv.org\/content\/10.1101\/2025.01.17.633634v1.full (2025).","DOI":"10.1101\/2025.01.17.633634"},{"key":"2923_CR116","doi-asserted-by":"crossref","unstructured":"Taylor, R. C. & Dillin, A. Aging as an event of proteostasis collapse. Cold Spring Harb. Perspect. Biol. 3, a004440 (2011).","DOI":"10.1101\/cshperspect.a004440"},{"key":"2923_CR117","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1189\/jlb.0809562","volume":"87","author":"Y Chen","year":"2010","unstructured":"Chen, Y., Gorelik, G. J., Strickland, F. M. & Richardson, B. C. Decreased ERK and JNK signaling contribute to gene overexpression in \u201csenescent\u201d CD4+CD28- T cells through epigenetic mechanisms. J. Leukoc. Biol. 87, 137\u2013145 (2010).","journal-title":"J. Leukoc. Biol."},{"key":"2923_CR118","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.clim.2008.08.009","volume":"130","author":"Y Liu","year":"2009","unstructured":"Liu, Y., Kuick, R., Hanash, S. & Richardson, B. DNA methylation inhibition increases T cell KIR expression through effects on both promoter methylation and transcription factors. Clin. Immunol. 130, 213\u2013224 (2009).","journal-title":"Clin. Immunol."},{"key":"2923_CR119","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.it.2009.03.013","volume":"30","author":"NP Weng","year":"2009","unstructured":"Weng, N. P., Akbar, A. N. & Goronzy, J. CD28(-) T cells: their role in the age-associated decline of immune function. Trends Immunol. 30, 306\u2013312 (2009).","journal-title":"Trends Immunol."},{"key":"2923_CR120","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.exger.2009.12.008","volume":"45","author":"Y Li","year":"2010","unstructured":"Li, Y., Liu, Y., Strickland, F. M. & Richardson, B. Age-dependent decreases in DNA methyltransferase levels and low transmethylation micronutrient levels synergize to promote overexpression of genes implicated in autoimmunity and acute coronary syndromes. Exp. Gerontol. 45, 312\u2013322 (2010).","journal-title":"Exp. Gerontol."},{"key":"2923_CR121","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1371\/journal.pbio.0060301","volume":"6","author":"JP Copp\u00e9","year":"2008","unstructured":"Copp\u00e9, J. P. et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 6, 2853\u20132868 (2008).","journal-title":"PLoS Biol."},{"key":"2923_CR122","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.coi.2004.01.009","volume":"16","author":"FT Hakim","year":"2004","unstructured":"Hakim, F. T., Flomerfelt, F. A., Boyiadzis, M. & Gress, R. E. Aging, immunity and cancer. Curr. Opin. Immunol. 16, 151\u2013156 (2004).","journal-title":"Curr. Opin. Immunol."},{"key":"2923_CR123","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41577-019-0180-1","volume":"19","author":"JJ Goronzy","year":"2019","unstructured":"Goronzy, J. J. & Weyand, C. M. Mechanisms underlying T cell ageing. Nat. Rev. Immunol. 19, 573\u2013583 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"2923_CR124","doi-asserted-by":"crossref","unstructured":"Homann, L. et al. IFN-\u03b3 and TNF Induce Senescence and a Distinct Senescence-Associated Secretory Phenotype in Melanoma. Cells. 11, 1514 (2022).","DOI":"10.3390\/cells11091514"},{"key":"2923_CR125","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12979-025-00526-8","volume":"22","author":"L Gonz\u00e1lez-Osuna","year":"2025","unstructured":"Gonz\u00e1lez-Osuna, L. et al. p38 mitogen-activated protein kinase drives senescence in CD4+ T lymphocytes and increases their pathological potential. Immun. Ageing 22, 30 (2025).","journal-title":"Immun. Ageing"},{"key":"2923_CR126","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3389\/fcell.2019.00213","volume":"7","author":"F Macian","year":"2019","unstructured":"Macian, F. Autophagy in T Cell Function and Aging. Front. Cell Dev. Biol. 7, 213 (2019).","journal-title":"Front. Cell Dev. Biol."},{"key":"2923_CR127","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1126\/science.aax0860","volume":"368","author":"G Desd\u00edn-Mic\u00f3","year":"2020","unstructured":"Desd\u00edn-Mic\u00f3, G. et al. T cells with dysfunctional mitochondria induce multimorbidity and premature senescence. Science 368, 1371\u20131376 (2020).","journal-title":"Science"},{"key":"2923_CR128","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.cmet.2019.06.016","volume":"30","author":"Y Li","year":"2019","unstructured":"Li, Y. et al. The DNA Repair Nuclease MRE11A Functions as a Mitochondrial Protector and Prevents T Cell Pyroptosis and Tissue Inflammation. Cell Metab. 30, 477\u2013492.e476 (2019).","journal-title":"Cell Metab."},{"key":"2923_CR129","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nature07317","volume":"455","author":"H Ishikawa","year":"2008","unstructured":"Ishikawa, H. & Barber, G. N. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455, 674\u2013678 (2008).","journal-title":"Nature"},{"key":"2923_CR130","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/nature08476","volume":"461","author":"H Ishikawa","year":"2009","unstructured":"Ishikawa, H., Ma, Z. & Barber, G. N. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461, 788\u2013792 (2009).","journal-title":"Nature"},{"key":"2923_CR131","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.1074\/jbc.RA119.010734","volume":"295","author":"X Han","year":"2020","unstructured":"Han, X. et al. Autolysosomal degradation of cytosolic chromatin fragments antagonizes oxidative stress-induced senescence. J. Biol. Chem. 295, 4451\u20134463 (2020).","journal-title":"J. Biol. Chem."},{"key":"2923_CR132","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.912825","volume":"13","author":"X Qi","year":"2022","unstructured":"Qi, X. et al. Curcumol Suppresses CCF-Mediated Hepatocyte Senescence Through Blocking LC3B-Lamin B1 Interaction in Alcoholic Fatty Liver Disease. Front. Pharm. 13, 912825 (2022).","journal-title":"Front. Pharm."},{"key":"2923_CR133","doi-asserted-by":"publisher","first-page":"1559494","DOI":"10.3389\/fimmu.2025.1559494","volume":"16","author":"MA Daniels","year":"2025","unstructured":"Daniels, M. A. & Teixeiro, E. The NF-\u03baB signaling network in the life of T cells. Front. Immunol. 16, 1559494 (2025).","journal-title":"Front. Immunol."},{"key":"2923_CR134","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/sj.cdd.4401557","volume":"12","author":"S Gupta","year":"2005","unstructured":"Gupta, S. et al. Role of NF-kappaB signaling pathway in increased tumor necrosis factor-alpha-induced apoptosis of lymphocytes in aged humans. Cell Death Differ. 12, 177\u2013183 (2005).","journal-title":"Cell Death Differ."},{"key":"2923_CR135","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10875-006-9019-1","volume":"26","author":"S Gupta","year":"2006","unstructured":"Gupta, S., Su, H., Bi, R. & Gollapudi, S. Differential sensitivity of na\u00efve and memory subsets of human CD8+ T cells to TNF-alpha-induced apoptosis. J. Clin. Immunol. 26, 193\u2013203 (2006).","journal-title":"J. Clin. Immunol."},{"key":"2923_CR136","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0531-5565(99)00033-9","volume":"34","author":"C Spaulding","year":"1999","unstructured":"Spaulding, C., Guo, W. & Effros, R. B. Resistance to apoptosis in human CD8+ T cells that reach replicative senescence after multiple rounds of antigen-specific proliferation. Exp. Gerontol. 34, 633\u2013644 (1999).","journal-title":"Exp. Gerontol."},{"key":"2923_CR137","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.4049\/jimmunol.161.2.1018","volume":"161","author":"M Schirmer","year":"1998","unstructured":"Schirmer, M., Vallejo, A. N., Weyand, C. M. & Goronzy, J. J. Resistance to apoptosis and elevated expression of Bcl-2 in clonally expanded CD4+CD28- T cells from rheumatoid arthritis patients. J. Immunol. 161, 1018\u20131025 (1998).","journal-title":"J. Immunol."},{"key":"2923_CR138","doi-asserted-by":"publisher","first-page":"6301","DOI":"10.4049\/jimmunol.165.11.6301","volume":"165","author":"AN Vallejo","year":"2000","unstructured":"Vallejo, A. N., Schirmer, M., Weyand, C. M. & Goronzy, J. J. Clonality and longevity of CD4+CD28null T cells are associated with defects in apoptotic pathways. J. Immunol. 165, 6301\u20136307 (2000).","journal-title":"J. Immunol."},{"key":"2923_CR139","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1161\/CIRCULATIONAHA.114.013710","volume":"131","author":"E Kovalcsik","year":"2015","unstructured":"Kovalcsik, E. et al. Proteasome-mediated reduction in proapoptotic molecule Bim renders CD4\u207aCD28null T cells resistant to apoptosis in acute coronary syndrome. Circulation 131, 709\u2013720 (2015).","journal-title":"Circulation"},{"key":"2923_CR140","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1742-4933-3-5","volume":"3","author":"S Gupta","year":"2006","unstructured":"Gupta, S. et al. A paradox of immunodeficiency and inflammation in human aging: lessons learned from apoptosis. Immun. Ageing 3, 5 (2006).","journal-title":"Immun. Ageing"},{"key":"2923_CR141","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.molimm.2017.01.025","volume":"85","author":"K Pyaram","year":"2017","unstructured":"Pyaram, K., Sen, J. M. & Chang, C. H. Temporal regulation of Wnt\/\u03b2-catenin signaling is important for invariant NKT cell development and terminal maturation. Mol. Immunol. 85, 47\u201356 (2017).","journal-title":"Mol. Immunol."},{"key":"2923_CR142","doi-asserted-by":"publisher","first-page":"9777","DOI":"10.1073\/pnas.0914127107","volume":"107","author":"G Jeannet","year":"2010","unstructured":"Jeannet, G. et al. Essential role of the Wnt pathway effector Tcf-1 for the establishment of functional CD8 T cell memory. Proc. Natl. Acad. Sci. USA 107, 9777\u20139782 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2923_CR143","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s12026-009-8137-2","volume":"47","author":"Q Yu","year":"2010","unstructured":"Yu, Q., Sharma, A. & Sen, J. M. TCF1 and beta-catenin regulate T cell development and function. Immunol. Res. 47, 45\u201355 (2010).","journal-title":"Immunol. Res."},{"key":"2923_CR144","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nri2360","volume":"8","author":"FJ Staal","year":"2008","unstructured":"Staal, F. J., Luis, T. C. & Tiemessen, M. M. WNT signalling in the immune system: WNT is spreading its wings. Nat. Rev. Immunol. 8, 581\u2013593 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"2923_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14442-6","volume":"11","author":"H Kared","year":"2020","unstructured":"Kared, H. et al. Immunological history governs human stem cell memory CD4 heterogeneity via the Wnt signaling pathway. Nat. Commun. 11, 821 (2020).","journal-title":"Nat. Commun."},{"key":"2923_CR146","doi-asserted-by":"publisher","DOI":"10.1038\/srep13107","volume":"5","author":"L Tserel","year":"2015","unstructured":"Tserel, L. et al. Age-related profiling of DNA methylation in CD8+ T cells reveals changes in immune response and transcriptional regulator genes. Sci. Rep. 5, 13107 (2015).","journal-title":"Sci. Rep."},{"key":"2923_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2023.101800","volume":"69","author":"I Sturmlechner","year":"2023","unstructured":"Sturmlechner, I. et al. T cell fate decisions during memory cell generation with aging. Semin. Immunol. 69, 101800 (2023).","journal-title":"Semin. Immunol."},{"key":"2923_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108674","volume":"34","author":"A Delpoux","year":"2021","unstructured":"Delpoux, A. et al. FOXO1 constrains activation and regulates senescence in CD8 T cells. Cell Rep. 34, 108674 (2021).","journal-title":"Cell Rep."},{"key":"2923_CR149","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.mad.2011.04.007","volume":"132","author":"Z Varecza","year":"2011","unstructured":"Varecza, Z. et al. Multiple suppression pathways of canonical Wnt signalling control thymic epithelial senescence. Mech. Ageing Dev. 132, 249\u2013256 (2011).","journal-title":"Mech. Ageing Dev."},{"key":"2923_CR150","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/gerona\/glu030","volume":"70","author":"S Ferrando-Mart\u00ednez","year":"2015","unstructured":"Ferrando-Mart\u00ednez, S. et al. WNT signaling suppression in the senescent human thymus. J. Gerontol. A Biol. Sci. Med. Sci. 70, 273\u2013281 (2015).","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"2923_CR151","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.celrep.2015.07.008","volume":"12","author":"AV Griffith","year":"2015","unstructured":"Griffith, A. V. et al. Metabolic Damage and Premature Thymus Aging Caused by Stromal Catalase Deficiency. Cell Rep. 12, 1071\u20131079 (2015).","journal-title":"Cell Rep."},{"key":"2923_CR152","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.669893","volume":"12","author":"GE Marcovecchio","year":"2021","unstructured":"Marcovecchio, G. E. et al. Premature Senescence and Increased Oxidative Stress in the Thymus of Down Syndrome Patients. Front. Immunol. 12, 669893 (2021).","journal-title":"Front. Immunol."},{"key":"2923_CR153","doi-asserted-by":"publisher","first-page":"5678","DOI":"10.4049\/jimmunol.1502010","volume":"195","author":"I Rode","year":"2015","unstructured":"Rode, I. et al. Foxn1 Protein Expression in the Developing, Aging, and Regenerating Thymus. J. Immunol. 195, 5678\u20135687 (2015).","journal-title":"J. Immunol."},{"key":"2923_CR154","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12979-015-0045-9","volume":"12","author":"MD Reis","year":"2015","unstructured":"Reis, M. D. et al. Decline of FOXN1 gene expression in human thymus correlates with age: possible epigenetic regulation. Immun. Ageing 12, 18 (2015).","journal-title":"Immun. Ageing"},{"key":"2923_CR155","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41392-023-01608-z","volume":"8","author":"V Panwar","year":"2023","unstructured":"Panwar, V. et al. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal Transduct. Target Ther. 8, 375 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2923_CR156","doi-asserted-by":"crossref","unstructured":"Cayo, A. et al. mTOR Activity and Autophagy in Senescent Cells, a Complex Partnership. Int J Mol Sci. 22, 8149 (2021).","DOI":"10.3390\/ijms22158149"},{"key":"2923_CR157","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41420-025-02468-y","volume":"11","author":"L Liu","year":"2025","unstructured":"Liu, L. et al. Metabolic reprogramming in T cell senescence: a novel strategy for cancer immunotherapy. Cell Death Discov. 11, 161 (2025).","journal-title":"Cell Death Discov."},{"key":"2923_CR158","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/ni.3314","volume":"17","author":"JL Hukelmann","year":"2016","unstructured":"Hukelmann, J. L. et al. The cytotoxic T cell proteome and its shaping by the kinase mTOR. Nat. Immunol. 17, 104\u2013112 (2016).","journal-title":"Nat. Immunol."},{"key":"2923_CR159","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0531-5565(99)00058-3","volume":"34","author":"M Drouet","year":"1999","unstructured":"Drouet, M. et al. Age-associated changes in mitochondrial parameters on peripheral human lymphocytes. Exp. Gerontol. 34, 843\u2013852 (1999).","journal-title":"Exp. Gerontol."},{"key":"2923_CR160","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/jb\/mvae032","volume":"176","author":"S Kawakami","year":"2024","unstructured":"Kawakami, S., Johmura, Y. & Nakanishi, M. Intracellular acidification and glycolysis modulate inflammatory pathway in senescent cells. J. Biochem 176, 97\u2013108 (2024).","journal-title":"J. Biochem"},{"key":"2923_CR161","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.3389\/fimmu.2018.01618","volume":"9","author":"ES Egorov","year":"2018","unstructured":"Egorov, E. S. et al. The Changing Landscape of Naive T Cell Receptor Repertoire With Human Aging. Front. Immunol. 9, 1618 (2018).","journal-title":"Front. Immunol."},{"key":"2923_CR162","doi-asserted-by":"crossref","unstructured":"Sun, X. et al. Longitudinal analysis reveals age-related changes in the T cell receptor repertoire of human T cell subsets. J. Clin. Invest. 132, e158122 (2022).","DOI":"10.1172\/JCI158122"},{"key":"2923_CR163","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3389\/fimmu.2018.00448","volume":"9","author":"MJ Kallemeijn","year":"2018","unstructured":"Kallemeijn, M. J. et al. Next-Generation Sequencing Analysis of the Human TCR\u03b3\u03b4+ T-Cell Repertoire Reveals Shifts in V\u03b3- and V\u03b4-Usage in Memory Populations upon Aging. Front. Immunol. 9, 448 (2018).","journal-title":"Front. Immunol."},{"key":"2923_CR164","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.4049\/jimmunol.1003013","volume":"186","author":"BD Rudd","year":"2011","unstructured":"Rudd, B. D., Venturi, V., Davenport, M. P. & Nikolich-Zugich, J. Evolution of the antigen-specific CD8+ TCR repertoire across the life span: evidence for clonal homogenization of the old TCR repertoire. J. Immunol. 186, 2056\u20132064 (2011).","journal-title":"J. Immunol."},{"key":"2923_CR165","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/s41590-024-01804-1","volume":"25","author":"N Fortelny","year":"2024","unstructured":"Fortelny, N. et al. JAK-STAT signaling maintains homeostasis in T cells and macrophages. Nat. Immunol. 25, 847\u2013859 (2024).","journal-title":"Nat. Immunol."},{"key":"2923_CR166","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.806906","volume":"13","author":"G Toma","year":"2022","unstructured":"Toma, G. et al. Transcriptional Analysis of Total CD8+ T cells and CD8+CD45RA- memory T cells from young and old healthy blood donors. Front. Immunol. 13, 806906 (2022).","journal-title":"Front. Immunol."},{"key":"2923_CR167","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adm7269","volume":"17","author":"F Ma","year":"2025","unstructured":"Ma, F. et al. Tumor extracellular vesicle-derived PD-L1 promotes T cell senescence through lipid metabolism reprogramming. Sci. Transl. Med. 17, eadm7269 (2025).","journal-title":"Sci. Transl. Med."},{"key":"2923_CR168","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s40778-018-0128-6","volume":"4","author":"AK Singh","year":"2018","unstructured":"Singh, A. K., Althoff, M. J. & Cancelas, J. A. Signaling Pathways Regulating Hematopoietic Stem Cell and Progenitor Aging. Curr. Stem Cell Rep. 4, 166\u2013181 (2018).","journal-title":"Curr. Stem Cell Rep."},{"key":"2923_CR169","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13996","volume":"22","author":"E Zukowski","year":"2023","unstructured":"Zukowski, E. et al. STAT3 modulates CD4+ T mitochondrial dynamics and function in aging. Aging Cell 22, e13996 (2023).","journal-title":"Aging Cell"},{"key":"2923_CR170","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02689-5","volume":"9","author":"X Liu","year":"2018","unstructured":"Liu, X. et al. Regulatory T cells trigger effector T cell DNA damage and senescence caused by metabolic competition. Nat. Commun. 9, 249 (2018).","journal-title":"Nat. Commun."},{"key":"2923_CR171","doi-asserted-by":"publisher","first-page":"262","DOI":"10.4049\/jimmunol.178.1.262","volume":"178","author":"Y Seki","year":"2007","unstructured":"Seki, Y. et al. IL-7\/STAT5 cytokine signaling pathway is essential but insufficient for maintenance of naive CD4 T cell survival in peripheral lymphoid organs. J. Immunol. 178, 262\u2013270 (2007).","journal-title":"J. Immunol."},{"key":"2923_CR172","unstructured":"Arango-Franco, C. A. et al. IL-7-dependent and -independent lineages of IL-7R-dependent human T cells. J. Clin. Invest. 134, 3370\u201381 (2024)."},{"key":"2923_CR173","doi-asserted-by":"publisher","first-page":"658263","DOI":"10.3389\/fimmu.2021.658263","volume":"12","author":"F Morandi","year":"2021","unstructured":"Morandi, F., Horenstein, A. L. & Malavasi, F. The Key Role of NAD+ in Anti-Tumor Immune Response: An Update. Front. Immunol. 12, 658263 (2021).","journal-title":"Front. Immunol."},{"key":"2923_CR174","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrm3376","volume":"13","author":"BA Gibson","year":"2012","unstructured":"Gibson, B. A. & Kraus, W. L. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat. Rev. Mol. Cell Biol. 13, 411\u2013424 (2012).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2923_CR175","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/j.cell.2013.11.037","volume":"155","author":"AP Gomes","year":"2013","unstructured":"Gomes, A. P. et al. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell 155, 1624\u20131638 (2013).","journal-title":"Cell"},{"key":"2923_CR176","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.cell.2014.03.026","volume":"157","author":"EF Fang","year":"2014","unstructured":"Fang, E. F. et al. Defective mitophagy in XPA via PARP-1 hyperactivation and NAD(+)\/SIRT1 reduction. Cell 157, 882\u2013896 (2014).","journal-title":"Cell"},{"key":"2923_CR177","doi-asserted-by":"crossref","unstructured":"Hope, H. C. et al. Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure. Nat Cancer 6, 1524\u20131536 (2025).","DOI":"10.1038\/s43018-025-00982-7"},{"key":"2923_CR178","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00262-024-03881-5","volume":"74","author":"LL Lv","year":"2025","unstructured":"Lv, L. L. et al. High CD38 expression defines a mitochondrial function-adapted CD8+ T cell subset with implications for lung cancer immunotherapy. Cancer Immunol. Immunother. 74, 49 (2025).","journal-title":"Cancer Immunol. Immunother."},{"key":"2923_CR179","doi-asserted-by":"publisher","first-page":"5893","DOI":"10.1172\/JCI136466","volume":"130","author":"Z Guo","year":"2020","unstructured":"Guo, Z. et al. DCAF1 regulates Treg senescence via the ROS axis during immunological aging. J. Clin. Invest. 130, 5893\u20135908 (2020).","journal-title":"J. Clin. Invest."},{"key":"2923_CR180","doi-asserted-by":"crossref","unstructured":"Kim, C. et al. Histone deficiency and accelerated replication stress in T cell aging. J. Clin. Invest. 131, e143632 (2021).","DOI":"10.1172\/JCI143632"},{"key":"2923_CR181","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05552-3","volume":"9","author":"Z Ye","year":"2018","unstructured":"Ye, Z. et al. Regulation of miR-181a expression in T cell aging. Nat. Commun. 9, 3060 (2018).","journal-title":"Nat. Commun."},{"key":"2923_CR182","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.immuni.2015.01.006","volume":"42","author":"GJ Martinez","year":"2015","unstructured":"Martinez, G. J. et al. The transcription factor NFAT promotes exhaustion of activated CD8\u207a T cells. Immunity 42, 265\u2013278 (2015).","journal-title":"Immunity"},{"key":"2923_CR183","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41590-021-00964-8","volume":"22","author":"H Seo","year":"2021","unstructured":"Seo, H. et al. BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. Nat. Immunol. 22, 983\u2013995 (2021).","journal-title":"Nat. Immunol."},{"key":"2923_CR184","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","volume":"571","author":"AC Scott","year":"2019","unstructured":"Scott, A. C. et al. TOX is a critical regulator of tumour-specific T cell differentiation. Nature 571, 270\u2013274 (2019).","journal-title":"Nature"},{"key":"2923_CR185","doi-asserted-by":"publisher","first-page":"12410","DOI":"10.1073\/pnas.1905675116","volume":"116","author":"H Seo","year":"2019","unstructured":"Seo, H. et al. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion. Proc. Natl. Acad. Sci. USA 116, 12410\u201312415 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2923_CR186","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","volume":"567","author":"J Chen","year":"2019","unstructured":"Chen, J. et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature 567, 530\u2013534 (2019).","journal-title":"Nature"},{"key":"2923_CR187","doi-asserted-by":"publisher","first-page":"e1483302","DOI":"10.1080\/2162402X.2018.1483302","volume":"7","author":"PS Redd","year":"2018","unstructured":"Redd, P. S. et al. H3K4me3 mediates the NF-\u03baB p50 homodimer binding to the pdcd1 promoter to activate PD-1 transcription in T cells. Oncoimmunology 7, e1483302 (2018).","journal-title":"Oncoimmunology"},{"key":"2923_CR188","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature11530","volume":"490","author":"P Li","year":"2012","unstructured":"Li, P. et al. BATF-JUN is critical for IRF4-mediated transcription in T cells. Nature 490, 543\u2013546 (2012).","journal-title":"Nature"},{"key":"2923_CR189","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.immuni.2017.11.021","volume":"47","author":"K Man","year":"2017","unstructured":"Man, K. et al. Transcription Factor IRF4 Promotes CD8+ T Cell Exhaustion and Limits the Development of Memory-like T Cells during Chronic Infection. Immunity 47, 1129\u20131141.e1125 (2017).","journal-title":"Immunity"},{"key":"2923_CR190","doi-asserted-by":"crossref","unstructured":"Sun, Q. et al. STAT3 regulates CD8+ T cell differentiation and functions in cancer and acute infection. J. Exp. Med. 220, e20220686 (2023).","DOI":"10.1084\/jem.20220686"},{"key":"2923_CR191","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28523-1","volume":"13","author":"VM Ravi","year":"2022","unstructured":"Ravi, V. M. et al. T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10. Nat. Commun. 13, 925 (2022).","journal-title":"Nat. Commun."},{"key":"2923_CR192","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1158\/2326-6066.CIR-24-0894","volume":"13","author":"L Huang","year":"2025","unstructured":"Huang, L. et al. T-cell Senescence in the Tumor Microenvironment. Cancer Immunol. Res. 13, 618\u2013632 (2025).","journal-title":"Cancer Immunol. Res."},{"key":"2923_CR193","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/bmt.2015.345","volume":"51","author":"M Bregni","year":"2016","unstructured":"Bregni, M., Badoglio, M., Pedrazzoli, P. & Lanza, F. Is allogeneic transplant for solid tumors still alive? Bone Marrow Transpl. 51, 751\u2013752 (2016).","journal-title":"Bone Marrow Transpl."},{"key":"2923_CR194","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","volume":"38","author":"V Leko","year":"2020","unstructured":"Leko, V. & Rosenberg, S. A. Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors. Cancer Cell 38, 454\u2013472 (2020).","journal-title":"Cancer Cell"},{"key":"2923_CR195","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","volume":"173","author":"JM Chemnitz","year":"2004","unstructured":"Chemnitz, J. M. et al. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173, 945\u2013954 (2004).","journal-title":"J. Immunol."},{"key":"2923_CR196","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1126\/science.aaf1292","volume":"355","author":"E Hui","year":"2017","unstructured":"Hui, E. et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science 355, 1428\u20131433 (2017).","journal-title":"Science"},{"key":"2923_CR197","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","volume":"33","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf, D. et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J. Clin. Oncol. 33, 1889\u20131894 (2015).","journal-title":"J. Clin. Oncol."},{"key":"2923_CR198","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow, M. A. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006\u20132017 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2923_CR199","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer, R. J. et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 373, 1803\u20131813 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2923_CR200","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer, J. et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N. Engl. J. Med. 373, 123\u2013135 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2923_CR201","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa, G. K. et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid. 1, EVIDoa2100070 (2022).","journal-title":"NEJM Evid."},{"key":"2923_CR202","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles, T. et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N. Engl. J. Med. 383, 1218\u20131230 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2923_CR203","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.jtho.2023.03.008","volume":"18","author":"T Makharadze","year":"2023","unstructured":"Makharadze, T. et al. Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial. J. Thorac. Oncol. 18, 755\u2013768 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"2923_CR204","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","volume":"388","author":"MR Mirza","year":"2023","unstructured":"Mirza, M. R. et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N. Engl. J. Med. 388, 2145\u20132158 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2923_CR205","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/cas.13424","volume":"109","author":"K Mimura","year":"2018","unstructured":"Mimura, K. et al. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci. 109, 43\u201353 (2018).","journal-title":"Cancer Sci."},{"key":"2923_CR206","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest"},{"key":"2923_CR207","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1074-7613(00)80158-2","volume":"12","author":"S Ikemizu","year":"2000","unstructured":"Ikemizu, S. et al. Structure and dimerization of a soluble form of B7-1. Immunity 12, 51\u201360 (2000).","journal-title":"Immunity"},{"key":"2923_CR208","doi-asserted-by":"publisher","first-page":"5155","DOI":"10.1182\/blood-2011-11-388918","volume":"119","author":"X Tai","year":"2012","unstructured":"Tai, X. et al. Basis of CTLA-4 function in regulatory and conventional CD4(+) T cells. Blood 119, 5155\u20135163 (2012).","journal-title":"Blood"},{"key":"2923_CR209","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","volume":"20","author":"RJ Motzer","year":"2019","unstructured":"Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 20, 1370\u20131385 (2019).","journal-title":"Lancet Oncol."},{"key":"2923_CR210","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann, M. D. et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N. Engl. J. Med. 381, 2020\u20132031 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2923_CR211","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","volume":"392","author":"JD Wolchok","year":"2025","unstructured":"Wolchok, J. D. et al. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 392, 11\u201322 (2025).","journal-title":"N. Engl. J. Med."},{"key":"2923_CR212","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","volume":"27","author":"T Cascone","year":"2021","unstructured":"Cascone, T. et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat. Med. 27, 504\u2013514 (2021).","journal-title":"Nat. Med."},{"key":"2923_CR213","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40164-019-0150-0","volume":"8","author":"K Wu","year":"2019","unstructured":"Wu, K. et al. The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis. Exp. Hematol. Oncol. 8, 26 (2019).","journal-title":"Exp. Hematol. Oncol."},{"key":"2923_CR214","doi-asserted-by":"publisher","first-page":"22699","DOI":"10.1073\/pnas.1821218116","volume":"116","author":"SC Wei","year":"2019","unstructured":"Wei, S. C. et al. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proc. Natl. Acad. Sci. USA 116, 22699\u201322709 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2923_CR215","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang, D. Y. et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 4, 1721\u20131728 (2018).","journal-title":"JAMA Oncol."},{"key":"2923_CR216","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","volume":"5","author":"G De Velasco","year":"2017","unstructured":"De Velasco, G. et al. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1\/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol. Res. 5, 312\u2013318 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"2923_CR217","doi-asserted-by":"crossref","unstructured":"Yu, Y. et al. T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities. Adv. Sci. 13, e20634, (2026).","DOI":"10.1002\/advs.202520634"},{"key":"2923_CR218","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41571-022-00650-0","volume":"19","author":"P Sidaway","year":"2022","unstructured":"Sidaway, P. Tiragolumab active in PD-L1+ NSCLC. Nat. Rev. Clin. Oncol. 19, 428 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2923_CR219","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41586-024-07121-9","volume":"627","author":"X Guan","year":"2024","unstructured":"Guan, X. et al. Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells. Nature 627, 646\u2013655 (2024).","journal-title":"Nature"},{"key":"2923_CR220","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi, H. A. et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N. Engl. J. Med. 386, 24\u201334 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2923_CR221","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1016\/j.cell.2024.07.016","volume":"187","author":"LP Andrews","year":"2024","unstructured":"Andrews, L. P. et al. LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-gamma dependent anti-tumor immunity. Cell 187, 4355\u20134372.e4322 (2024).","journal-title":"Cell"},{"key":"2923_CR222","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai, L., Li, Y., Tan, J. & Xu, L. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J. Hematol. Oncol. 16, 101 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"2923_CR223","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","volume":"6","author":"S Maleki Vareki","year":"2018","unstructured":"Maleki Vareki, S. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J. Immunother. Cancer 6, 157 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"2923_CR224","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s43856-024-00687-5","volume":"4","author":"RM Barnett","year":"2024","unstructured":"Barnett, R. M. et al. Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers. Commun. Med. 4, 256 (2024).","journal-title":"Commun. Med."},{"key":"2923_CR225","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1634\/theoncologist.2018-0179","volume":"23","author":"ED Pulte","year":"2018","unstructured":"Pulte, E. D. et al. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia. Oncologist 23, 1366\u20131371 (2018).","journal-title":"Oncologist"},{"key":"2923_CR226","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01003-z","volume":"14","author":"M Mohan","year":"2024","unstructured":"Mohan, M. et al. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J. 14, 35 (2024).","journal-title":"Blood Cancer J."},{"key":"2923_CR227","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa2406536","volume":"392","author":"YC Cohen","year":"2025","unstructured":"Cohen, Y. C. et al. Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma. N. Engl. J. Med. 392, 138\u2013149 (2025).","journal-title":"N. Engl. J. Med."},{"key":"2923_CR228","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin, A. M. et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat. Med. 29, 2259\u20132267 (2023).","journal-title":"Nat. Med."},{"key":"2923_CR229","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.24.01008","volume":"42","author":"N Bumma","year":"2024","unstructured":"Bumma, N. et al. Linvoseltamab for Treatment of Relapsed\/Refractory Multiple Myeloma. J. Clin. Oncol. 42, 2702\u20132712 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2923_CR230","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde, L. E. et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 23, 1055\u20131065 (2022).","journal-title":"Lancet Oncol."},{"key":"2923_CR231","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","volume":"38","author":"C Thieblemont","year":"2024","unstructured":"Thieblemont, C. et al. Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia 38, 2653\u20132662 (2024).","journal-title":"Leukemia"},{"key":"2923_CR232","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s43018-025-00921-6","volume":"6","author":"WS Kim","year":"2025","unstructured":"Kim, W. S. et al. Odronextamab monotherapy in patients with relapsed\/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial. Nat. Cancer 6, 528\u2013539 (2025).","journal-title":"Nat. Cancer"},{"key":"2923_CR233","doi-asserted-by":"crossref","unstructured":"Liu, Y. et al. FDA Approval Summary: Tarlatamab for the Treatment of Extensive Stage Small Cell Lung Cancer. Clin. Cancer Res. 32, 1191\u20131195 (2026).","DOI":"10.1158\/1078-0432.CCR-25-2287"},{"key":"2923_CR234","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","volume":"26","author":"MR Middleton","year":"2020","unstructured":"Middleton, M. R. et al. Tebentafusp, A TCR\/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. Clin. Cancer Res. 26, 5869\u20135878 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2923_CR235","doi-asserted-by":"crossref","unstructured":"Staflin, K. et al. Target arm affinities determine preclinical efficacy and safety of anti-HER2\/CD3 bispecific antibody. JCI Insight. 5, e133757 (2020).","DOI":"10.1172\/jci.insight.133757"},{"key":"2923_CR236","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson, M. J. et al. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N. Engl. J. Med. 387, 2220\u20132231 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2923_CR237","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41375-025-02841-x","volume":"40","author":"N Bar","year":"2026","unstructured":"Bar, N. et al. Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study. Leukemia 40, 481\u2013490 (2026).","journal-title":"Leukemia"},{"key":"2923_CR238","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/s43018-024-00821-1","volume":"5","author":"L Carretero-Iglesia","year":"2024","unstructured":"Carretero-Iglesia, L. et al. ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells. Nat. Cancer 5, 1494\u20131514 (2024).","journal-title":"Nat. Cancer"},{"key":"2923_CR239","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1182\/blood.2022016243","volume":"140","author":"L Zhao","year":"2022","unstructured":"Zhao, L. et al. A novel CD19\/CD22\/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL. Blood 140, 1790\u20131802 (2022).","journal-title":"Blood"},{"key":"2923_CR240","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","volume":"33","author":"KK Patel","year":"2025","unstructured":"Patel, K. K. et al. From concept to cure: The evolution of CAR-T cell therapy. Mol. Ther. 33, 2123\u20132140 (2025).","journal-title":"Mol. Ther."},{"key":"2923_CR241","doi-asserted-by":"crossref","unstructured":"Chesney, J. et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 10, e005755 (2022).","DOI":"10.1136\/jitc-2022-005755"},{"key":"2923_CR242","doi-asserted-by":"publisher","first-page":"104671","DOI":"10.1016\/j.critrevonc.2025.104671","volume":"209","author":"U Mony","year":"2025","unstructured":"Mony, U. & Veeraraghavan, V. P. Outcomes of tumor-infiltrating lymphocyte therapy in solid tumours - A systematic review and meta analysis. Crit. Rev. Oncol. Hematol. 209, 104671 (2025).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2923_CR243","doi-asserted-by":"publisher","first-page":"8878","DOI":"10.1158\/0008-5472.CAN-06-1450","volume":"66","author":"CJ Cohen","year":"2006","unstructured":"Cohen, C. J. et al. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR\/CD3 stability. Cancer Res. 66, 8878\u20138886 (2006).","journal-title":"Cancer Res."},{"key":"2923_CR244","doi-asserted-by":"publisher","first-page":"6232","DOI":"10.4049\/jimmunol.0902047","volume":"184","author":"G Bialer","year":"2010","unstructured":"Bialer, G. et al. Selected murine residues endow human TCR with enhanced tumor recognition. J. Immunol. 184, 6232\u20136241 (2010).","journal-title":"J. Immunol."},{"key":"2923_CR245","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1158\/0008-5472.CAN-06-3986","volume":"67","author":"CJ Cohen","year":"2007","unstructured":"Cohen, C. J. et al. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 67, 3898\u20133903 (2007).","journal-title":"Cancer Res."},{"key":"2923_CR246","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1182\/blood-2006-05-023069","volume":"109","author":"J Kuball","year":"2007","unstructured":"Kuball, J. et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 109, 2331\u20132338 (2007).","journal-title":"Blood"},{"key":"2923_CR247","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41392-019-0070-9","volume":"4","author":"D Li","year":"2019","unstructured":"Li, D. et al. Genetically engineered T cells for cancer immunotherapy. Signal Transduct. Target Ther. 4, 35 (2019).","journal-title":"Signal Transduct. Target Ther."},{"key":"2923_CR248","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1158\/1078-0432.CCR-25-0595","volume":"31","author":"KK Barnett","year":"2025","unstructured":"Barnett, K. K. et al. FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4-Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy. Clin. Cancer Res. 31, 3112\u20133117 (2025).","journal-title":"Clin. Cancer Res."},{"key":"2923_CR249","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1200\/JCO-25-00055","volume":"43","author":"E Hatipoglu","year":"2025","unstructured":"Hatipoglu, E., Furness, A. J. S. & Jones, R. L. Letetresgene Autoleucel: A Milestone in Treatment of Myxoid\/Round Cell Liposarcoma. J. Clin. Oncol. 43, 1755\u20131757 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2923_CR250","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1111\/cas.70048","volume":"116","author":"M Yang","year":"2025","unstructured":"Yang, M., Zhong, P., Jiao, H. & Wei, P. Features of HLA-A*02 in Identifying Eligible Patients for Tecelra TCR-T Therapy. Cancer Sci. 116, 2320\u20132322 (2025).","journal-title":"Cancer Sci."},{"key":"2923_CR251","doi-asserted-by":"publisher","first-page":"10972","DOI":"10.1073\/pnas.1005802107","volume":"107","author":"MM van Loenen","year":"2010","unstructured":"van Loenen, M. M. et al. Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc. Natl. Acad. Sci. USA 107, 10972\u201310977 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2923_CR252","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/nm.2128","volume":"16","author":"GM Bendle","year":"2010","unstructured":"Bendle, G. M. et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat. Med. 16, 565\u2013570 (2010).","journal-title":"Nat. Med."},{"key":"2923_CR253","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1038\/mt.2010.195","volume":"18","author":"SA Rosenberg","year":"2010","unstructured":"Rosenberg, S. A. Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells. Mol. Ther. 18, 1744\u20131745 (2010).","journal-title":"Mol. Ther."},{"key":"2923_CR254","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/med.21818","volume":"42","author":"H Hanssens","year":"2022","unstructured":"Hanssens, H. et al. The antigen-binding moiety in the driver\u2019s seat of CARs. Med Res Rev. 42, 306\u2013342 (2022).","journal-title":"Med Res Rev."},{"key":"2923_CR255","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","volume":"391","author":"C Roddie","year":"2024","unstructured":"Roddie, C. et al. Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia. N. Engl. J. Med. 391, 2219\u20132230 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2923_CR256","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2923_CR257","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"2923_CR258","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar, Z., Waks, T., Gross, G. & Schindler, D. G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA 90, 720\u2013724 (1993).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2923_CR259","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1177\/1535370215584936","volume":"240","author":"AE Firor","year":"2015","unstructured":"Firor, A. E., Jares, A. & Ma, Y. From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy. Exp. Biol. Med. 240, 1087\u20131098 (2015).","journal-title":"Exp. Biol. Med."},{"key":"2923_CR260","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/0167-5699(90)90085-N","volume":"11","author":"CH June","year":"1990","unstructured":"June, C. H., Ledbetter, J. A., Linsley, P. S. & Thompson, C. B. Role of the CD28 receptor in T-cell activation. Immunol. Today 11, 211\u2013216 (1990).","journal-title":"Immunol. Today"},{"key":"2923_CR261","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1084\/jem.188.4.619","volume":"188","author":"A Krause","year":"1998","unstructured":"Krause, A. et al. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J. Exp. Med. 188, 619\u2013626 (1998).","journal-title":"J. Exp. Med."},{"key":"2923_CR262","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abm1463","volume":"14","author":"DB Goodman","year":"2022","unstructured":"Goodman, D. B. et al. Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies. Sci. Transl. Med. 14, eabm1463 (2022).","journal-title":"Sci. Transl. Med."},{"key":"2923_CR263","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200815","volume":"32","author":"V Mikoli\u010d","year":"2024","unstructured":"Mikoli\u010d, V. et al. Toll-like receptor 4 signaling activation domains promote CAR T cell function against solid tumors. Mol. Ther. Oncol. 32, 200815 (2024).","journal-title":"Mol. Ther. Oncol."},{"key":"2923_CR264","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-022-01244-0","volume":"15","author":"J Tan","year":"2022","unstructured":"Tan, J. et al. Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells. J. Hematol. Oncol. 15, 39 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"2923_CR265","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41587-024-02446-2","volume":"43","author":"U Uslu","year":"2025","unstructured":"Uslu, U. & June, C. H. Beyond the blood: expanding CAR T cell therapy to solid tumors. Nat. Biotechnol. 43, 506\u2013515 (2025).","journal-title":"Nat. Biotechnol."},{"key":"2923_CR266","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","volume":"19","author":"RO Carpenter","year":"2013","unstructured":"Carpenter, R. O. et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin. Cancer Res. 19, 2048\u20132060 (2013).","journal-title":"Clin. Cancer Res."},{"key":"2923_CR267","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/d41573-021-00031-9","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard, A. FDA approves fourth CAR-T cell therapy. Nat. Rev. Drug Discov. 20, 166 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2923_CR268","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"NH Fowler","year":"2022","unstructured":"Fowler, N. H. et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat. Med. 28, 325\u2013332 (2022).","journal-title":"Nat. Med."},{"key":"2923_CR269","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2923_CR270","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2923_CR271","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah, B. D. et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 398, 491\u2013502 (2021).","journal-title":"Lancet"},{"key":"2923_CR272","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839\u2013852 (2020).","journal-title":"Lancet"},{"key":"2923_CR273","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2923_CR274","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson, C. A. et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 23, 91\u2013103 (2022).","journal-title":"Lancet Oncol."},{"key":"2923_CR275","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N. Engl. J. Med. 382, 1331\u20131342 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2923_CR276","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 20, 31\u201342 (2019).","journal-title":"Lancet Oncol."},{"key":"2923_CR277","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin, T. et al. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J. Clin. Oncol. 41, 1265\u20131274 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2923_CR278","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1182\/blood.2020006770","volume":"137","author":"J Gauthier","year":"2021","unstructured":"Gauthier, J. et al. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood 137, 323\u2013335 (2021).","journal-title":"Blood"},{"key":"2923_CR279","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1200\/JCO.20.02262","volume":"39","author":"NN Shah","year":"2021","unstructured":"Shah, N. N. et al. Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL. J. Clin. Oncol. 39, 1650\u20131659 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2923_CR280","doi-asserted-by":"crossref","unstructured":"Chong, E. A., Ruella, M., Schuster, S. J. & Lymphoma Program Investigators at the University of Pennsylvania. Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy. N Engl J Med. 384, 673\u2013674 (2021).","DOI":"10.1056\/NEJMc2030164"},{"key":"2923_CR281","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","volume":"15","author":"WH Zhao","year":"2022","unstructured":"Zhao, W. H. et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J. Hematol. Oncol. 15, 86 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"2923_CR282","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","volume":"619","author":"DJ Baker","year":"2023","unstructured":"Baker, D. J. et al. CAR T therapy beyond cancer: the evolution of a living drug. Nature 619, 707\u2013715 (2023).","journal-title":"Nature"},{"key":"2923_CR283","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown, C. E. et al. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N. Engl. J. Med. 375, 2561\u20132569 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2923_CR284","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner, R. G. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603, 934\u2013941 (2022).","journal-title":"Nature"},{"key":"2923_CR285","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat. Med. 28, 1189\u20131198 (2022).","journal-title":"Nat. Med."},{"key":"2923_CR286","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo, F. et al. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. N. Engl. J. Med. 388, 1284\u20131295 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2923_CR287","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.aaf2807","volume":"354","author":"KE Pauken","year":"2016","unstructured":"Pauken, K. E. et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354, 1160\u20131165 (2016).","journal-title":"Science"},{"key":"2923_CR288","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.cell.2017.06.007","volume":"170","author":"HE Ghoneim","year":"2017","unstructured":"Ghoneim, H. E. et al. De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation. Cell 170, 142\u2013157.e119 (2017).","journal-title":"Cell"},{"key":"2923_CR289","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.immuni.2016.07.008","volume":"45","author":"B Bengsch","year":"2016","unstructured":"Bengsch, B. et al. Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion. Immunity 45, 358\u2013373 (2016).","journal-title":"Immunity"},{"key":"2923_CR290","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02175-9","volume":"23","author":"MQ Yang","year":"2024","unstructured":"Yang, M. Q. et al. Targeting mitochondria: restoring the antitumor efficacy of exhausted T cells. Mol. Cancer 23, 260 (2024).","journal-title":"Mol. Cancer"},{"key":"2923_CR291","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7692","volume":"6","author":"N Patsoukis","year":"2015","unstructured":"Patsoukis, N. et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat. Commun. 6, 6692 (2015).","journal-title":"Nat. Commun."},{"key":"2923_CR292","doi-asserted-by":"crossref","unstructured":"Ando, S. et al. mTOR regulates T cell exhaustion and PD-1-targeted immunotherapy response during chronic viral infection. J Clin. Invest. 133, e160025 (2023).","DOI":"10.1172\/JCI160025"},{"key":"2923_CR293","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","volume":"38","author":"F Dammeijer","year":"2020","unstructured":"Dammeijer, F. et al. The PD-1\/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. Cancer Cell 38, 685\u2013700.e688 (2020).","journal-title":"Cancer Cell"},{"key":"2923_CR294","doi-asserted-by":"crossref","unstructured":"Liu, X. et al. Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy. J. Immunother Cancer. 10, e005020 (2022).","DOI":"10.1136\/jitc-2022-005020"},{"key":"2923_CR295","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41423-020-0427-6","volume":"18","author":"KH Kim","year":"2021","unstructured":"Kim, K. H. et al. PD-1 blockade-unresponsive human tumor-infiltrating CD8(+) T cells are marked by loss of CD28 expression and rescued by IL-15. Cell Mol. Immunol. 18, 385\u2013397 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"2923_CR296","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00513-0","volume":"8","author":"W Sun","year":"2024","unstructured":"Sun, W. et al. CD57-positive CD8\u2009+\u2009T cells define the response to anti-programmed cell death protein-1 immunotherapy in patients with advanced non-small cell lung cancer. NPJ Precis. Oncol. 8, 25 (2024).","journal-title":"NPJ Precis. Oncol."},{"key":"2923_CR297","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1182\/blood.2022015956","volume":"140","author":"N Philipp","year":"2022","unstructured":"Philipp, N. et al. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood 140, 1104\u20131118 (2022).","journal-title":"Blood"},{"key":"2923_CR298","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93842-0","volume":"11","author":"L Haber","year":"2021","unstructured":"Haber, L. et al. Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning. Sci. Rep. 11, 14397 (2021).","journal-title":"Sci. Rep."},{"key":"2923_CR299","doi-asserted-by":"crossref","unstructured":"Poussin, M. et al. Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies. J. Immunother Cancer. 9, e002444 (2021).","DOI":"10.1136\/jitc-2021-002444"},{"key":"2923_CR300","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2425781122","volume":"122","author":"A Leithner","year":"2025","unstructured":"Leithner, A. et al. Solution structure and synaptic analyses reveal determinants of bispecific T cell engager potency. Proc. Natl. Acad. Sci. USA 122, e2425781122 (2025).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2923_CR301","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.csbj.2020.05.006","volume":"18","author":"S Dickopf","year":"2020","unstructured":"Dickopf, S., Georges, G. J. & Brinkmann, U. Format and geometries matter: Structure-based design defines the functionality of bispecific antibodies. Comput Struct. Biotechnol. J. 18, 1221\u20131227 (2020).","journal-title":"Comput Struct. Biotechnol. J."},{"key":"2923_CR302","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1021\/acschembio.3c00728","volume":"19","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Geometric Antibody Engineering Reveals the Spatial Factor on the Efficacy of Bispecific T Cell Engagers. ACS Chem. Biol. 19, 916\u2013925 (2024).","journal-title":"ACS Chem. Biol."},{"key":"2923_CR303","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1158\/1535-7163.MCT-24-0846","volume":"24","author":"D Wu","year":"2025","unstructured":"Wu, D. et al. Optimization of a Novel 2 + 2 BCMA \u00d7 CD3 Bispecific Antibody for Minimized Cytokine Release and Potent Efficacy. Mol. Cancer Ther. 24, 1600\u20131610 (2025).","journal-title":"Mol. Cancer Ther."},{"key":"2923_CR304","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/s41416-025-03125-y","volume":"133","author":"G Albayrak","year":"2025","unstructured":"Albayrak, G., Wan, P. K., Fisher, K. & Seymour, L. W. T cell engagers: expanding horizons in oncology and beyond. Br. J. Cancer 133, 1241\u20131249 (2025).","journal-title":"Br. J. Cancer"},{"key":"2923_CR305","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","volume":"41","author":"MJ Friedrich","year":"2023","unstructured":"Friedrich, M. J. et al. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell 41, 711\u2013725.e716 (2023).","journal-title":"Cancer Cell"},{"key":"2923_CR306","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3324\/haematol.2023.283758","volume":"109","author":"M Casey","year":"2024","unstructured":"Casey, M. et al. Regulatory T cells hamper the efficacy of T-cell-engaging bispecific antibody therapy. Haematologica 109, 787\u2013798 (2024).","journal-title":"Haematologica"},{"key":"2923_CR307","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","volume":"9","author":"C Zelle-Rieser","year":"2016","unstructured":"Zelle-Rieser, C. et al. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J. Hematol. Oncol. 9, 116 (2016).","journal-title":"J. Hematol. Oncol."},{"key":"2923_CR308","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2409564122","volume":"122","author":"J Wang","year":"2025","unstructured":"Wang, J. et al. Drug-loaded bispecific T cell nanoengager overcomes T cell exhaustion for potent cancer immunotherapy. Proc. Natl. Acad. Sci. USA 122, e2409564122 (2025).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2923_CR309","doi-asserted-by":"crossref","unstructured":"Ayala Ceja, M. et al. CAR-T cell manufacturing: Major process parameters and next-generation strategies. J. Exp. Med. 221, e20230903 (2024).","DOI":"10.1084\/jem.20230903"},{"key":"2923_CR310","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563\u2013571 (2018).","journal-title":"Nat. Med."},{"key":"2923_CR311","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1046\/j.1365-2567.1996.d01-689.x","volume":"88","author":"FF Fagnoni","year":"1996","unstructured":"Fagnoni, F. F. et al. Expansion of cytotoxic CD8+ CD28- T cells in healthy ageing people, including centenarians. Immunology 88, 501\u2013507 (1996).","journal-title":"Immunology"},{"key":"2923_CR312","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1038\/leu.2016.84","volume":"30","author":"H Suen","year":"2016","unstructured":"Suen, H. et al. Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade. Leukemia 30, 1716\u20131724 (2016).","journal-title":"Leukemia"},{"key":"2923_CR313","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","volume":"9","author":"RK Das","year":"2019","unstructured":"Das, R. K., Vernau, L., Grupp, S. A. & Barrett, D. M. Na\u00efve T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers. Cancer Discov. 9, 492\u2013499 (2019).","journal-title":"Cancer Discov."},{"key":"2923_CR314","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1200\/JCO.23.01097","volume":"42","author":"G Iacoboni","year":"2024","unstructured":"Iacoboni, G. et al. Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy. J. Clin. Oncol. 42, 205\u2013217 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2923_CR315","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/CJI.0000000000000216","volume":"41","author":"TS Nowicki","year":"2018","unstructured":"Nowicki, T. S. et al. Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products. J. Immunother. 41, 248\u2013259 (2018).","journal-title":"J. Immunother."},{"key":"2923_CR316","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1189\/jlb.5HI0716-322RR","volume":"102","author":"P Guha","year":"2017","unstructured":"Guha, P. et al. Frontline Science: Functionally impaired geriatric CAR-T cells rescued by increased \u03b15\u03b21 integrin expression. J. Leukoc. Biol. 102, 201\u2013208 (2017).","journal-title":"J. Leukoc. Biol."},{"key":"2923_CR317","doi-asserted-by":"crossref","unstructured":"Rutella, S. et al. Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia. J. Clin. Invest. 132, e159579 (2022).","DOI":"10.1172\/JCI159579"},{"key":"2923_CR318","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1016\/j.ymthe.2025.03.019","volume":"33","author":"A Dreyzin","year":"2025","unstructured":"Dreyzin, A. et al. Immunophenotype of CAR T cells and apheresis products predicts response in CD22 CAR T cell trial for B cell acute lymphoblastic leukemia. Mol. Ther. 33, 3360\u20133374 (2025).","journal-title":"Mol. Ther."},{"key":"2923_CR319","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1182\/bloodadvances.2023012416","volume":"8","author":"G Ledergor","year":"2024","unstructured":"Ledergor, G. et al. CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 8, 3562\u20133575 (2024).","journal-title":"Blood Adv."},{"key":"2923_CR320","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41392-023-01659-2","volume":"8","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Characteristics of premanufacture CD8+ T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma. Signal Transduct. Target Ther. 8, 409 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2923_CR321","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.exger.2003.09.024","volume":"39","author":"RB Effros","year":"2004","unstructured":"Effros, R. B. Replicative senescence of CD8 T cells: effect on human ageing. Exp. Gerontol. 39, 517\u2013524 (2004).","journal-title":"Exp. Gerontol."},{"key":"2923_CR322","doi-asserted-by":"publisher","first-page":"4882","DOI":"10.1158\/1078-0432.CCR-10-2769","volume":"17","author":"RW Joseph","year":"2011","unstructured":"Joseph, R. W. et al. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin. Cancer Res. 17, 4882\u20134891 (2011).","journal-title":"Clin. Cancer Res."},{"key":"2923_CR323","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1484303","volume":"16","author":"G Kadyrzhanova","year":"2025","unstructured":"Kadyrzhanova, G. et al. Aging impairs CD8 T cell responses in adoptive T-cell therapy against solid tumors. Front. Immunol. 16, 1484303 (2025).","journal-title":"Front. Immunol."},{"key":"2923_CR324","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2025.102715","volume":"107","author":"S Qi","year":"2025","unstructured":"Qi, S. et al. Impacts of ageing on the efficacy of CAR-T cell therapy. Ageing Res. Rev. 107, 102715 (2025).","journal-title":"Ageing Res. Rev."},{"key":"2923_CR325","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.1182\/bloodadvances.2022007057","volume":"6","author":"A Cuffel","year":"2022","unstructured":"Cuffel, A. et al. Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma. Blood Adv. 6, 4657\u20134660 (2022).","journal-title":"Blood Adv."},{"key":"2923_CR326","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","volume":"4","author":"FL Locke","year":"2020","unstructured":"Locke, F. L. et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 4, 4898\u20134911 (2020).","journal-title":"Blood Adv."},{"key":"2923_CR327","doi-asserted-by":"crossref","unstructured":"Junkuhn, C. et al. Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin\u2019s lymphoma. J. Immunother Cancer. 13, e010709 (2025).","DOI":"10.1136\/jitc-2024-010709corr1"},{"key":"2923_CR328","first-page":"1481","volume":"35","author":"OO Onyema","year":"2015","unstructured":"Onyema, O. O. et al. Chemotherapy-induced changes and immunosenescence of CD8+ T-cells in patients with breast cancer. Anticancer Res. 35, 1481\u20131489 (2015).","journal-title":"Anticancer Res."},{"key":"2923_CR329","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00262-009-0753-0","volume":"59","author":"IH Chen","year":"2010","unstructured":"Chen, I. H. et al. Immune impairment in patients with terminal cancers: influence of cancer treatments and cytomegalovirus infection. Cancer Immunol. Immunother. 59, 323\u2013334 (2010).","journal-title":"Cancer Immunol. Immunother."},{"key":"2923_CR330","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01071-1","volume":"14","author":"T Kientega","year":"2024","unstructured":"Kientega, T. et al. Premature thymic functional senescence is a hallmark of childhood acute lymphoblastic leukemia survivorship. Blood Cancer J. 14, 96 (2024).","journal-title":"Blood Cancer J."},{"key":"2923_CR331","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3389\/fimmu.2017.00146","volume":"8","author":"D Saavedra","year":"2017","unstructured":"Saavedra, D., Garcia, B. & Lage, A. T Cell Subpopulations in Healthy Elderly and Lung Cancer Patients: Insights from Cuban Studies. Front. Immunol. 8, 146 (2017).","journal-title":"Front. Immunol."},{"key":"2923_CR332","doi-asserted-by":"crossref","unstructured":"Coppola, G. et al. Ex vivo expansion of melanoma tumor infiltrating lymphocytes leads to a dominant exhausted T cell population with lack of memory markers. Cancer Immunol. Res. 14, 861\u2013874 (2026).","DOI":"10.1158\/2326-6066.CIR-25-0798"},{"key":"2923_CR333","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.0105-2896.2006.00382.x","volume":"211","author":"MF Mescher","year":"2006","unstructured":"Mescher, M. F. et al. Signals required for programming effector and memory development by CD8+ T cells. Immunol. Rev. 211, 81\u201392 (2006).","journal-title":"Immunol. Rev."},{"key":"2923_CR334","doi-asserted-by":"publisher","first-page":"6619","DOI":"10.1182\/blood-2009-01-199588","volume":"113","author":"SM Henson","year":"2009","unstructured":"Henson, S. M. et al. KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells. Blood 113, 6619\u20136628 (2009).","journal-title":"Blood"},{"key":"2923_CR335","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jcyt.2013.10.013","volume":"16","author":"DM Barrett","year":"2014","unstructured":"Barrett, D. M. et al. Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. Cytotherapy 16, 619\u2013630 (2014).","journal-title":"Cytotherapy"},{"key":"2923_CR336","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.4049\/jimmunol.156.10.3587","volume":"156","author":"J Monteiro","year":"1996","unstructured":"Monteiro, J., Batliwalla, F., Ostrer, H. & Gregersen, P. K. Shortened telomeres in clonally expanded CD28-CD8+ T cells imply a replicative history that is distinct from their CD28+CD8+ counterparts. J. Immunol. 156, 3587\u20133590 (1996).","journal-title":"J. Immunol."},{"key":"2923_CR337","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1007\/s13238-019-0643-y","volume":"10","author":"J Zhou","year":"2019","unstructured":"Zhou, J. et al. Chimeric antigen receptor T (CAR-T) cells expanded with IL-7\/IL-15 mediate superior antitumor effects. Protein Cell 10, 764\u2013769 (2019).","journal-title":"Protein Cell"},{"key":"2923_CR338","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1038\/s41375-023-01966-1","volume":"37","author":"L Salz","year":"2023","unstructured":"Salz, L. et al. Culture expansion of CAR T cells results in aberrant DNA methylation that is associated with adverse clinical outcome. Leukemia 37, 1868\u20131878 (2023).","journal-title":"Leukemia"},{"key":"2923_CR339","doi-asserted-by":"crossref","unstructured":"Vu\u010dini\u0107, V. et al. Impact of cellular composition and T-cell senescence of mononuclear cell concentrates on the manufacturing process of chimeric antigen receptor (CAR) T-cells. Transfusion 65, 1650-1661 (2025).","DOI":"10.1111\/trf.18354"},{"key":"2923_CR340","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jcyt.2024.03.006","volume":"26","author":"F Mo","year":"2024","unstructured":"Mo, F. et al. Human platelet lysate enhances in vivo activity of CAR-V\u03b42 T cells by reducing cellular senescence and apoptosis. Cytotherapy 26, 858\u2013868 (2024).","journal-title":"Cytotherapy"},{"key":"2923_CR341","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41586-024-07018-7","volume":"626","author":"J Garcia","year":"2024","unstructured":"Garcia, J. et al. Naturally occurring T cell mutations enhance engineered T cell therapies. Nature 626, 626\u2013634 (2024).","journal-title":"Nature"},{"key":"2923_CR342","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nbt.3147","volume":"33","author":"M Obenaus","year":"2015","unstructured":"Obenaus, M. et al. Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice. Nat. Biotechnol. 33, 402\u2013407 (2015).","journal-title":"Nat. Biotechnol."},{"key":"2923_CR343","doi-asserted-by":"publisher","first-page":"6973","DOI":"10.1073\/pnas.1221609110","volume":"110","author":"S Zhong","year":"2013","unstructured":"Zhong, S. et al. T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. Proc. Natl. Acad. Sci. USA 110, 6973\u20136978 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2923_CR344","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1038\/s41590-025-02252-1","volume":"26","author":"MS Eggeb\u00f8","year":"2025","unstructured":"Eggeb\u00f8, M. S. et al. TCR-engineered T cells targeting a shared \u03b2-catenin mutation eradicate solid tumors. Nat. Immunol. 26, 1726\u20131736 (2025).","journal-title":"Nat. Immunol."},{"key":"2923_CR345","doi-asserted-by":"crossref","unstructured":"Woolaver, R. A. et al. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts. J Immunother Cancer. 9, e001615 (2021).","DOI":"10.1136\/jitc-2020-001615"},{"key":"2923_CR346","doi-asserted-by":"publisher","first-page":"8473","DOI":"10.1073\/pnas.97.15.8473","volume":"97","author":"V Attuil","year":"2000","unstructured":"Attuil, V. et al. Comparative T cell receptor repertoire selection by antigen after adoptive transfer: a glimpse at an antigen-specific preimmune repertoire. Proc. Natl. Acad. Sci. USA 97, 8473\u20138478 (2000).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2923_CR347","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1158\/2326-6066.CIR-19-0035","volume":"7","author":"P Sharma","year":"2019","unstructured":"Sharma, P., Harris, D. T., Stone, J. D. & Kranz, D. M. T-cell Receptors Engineered de novo for peptide specificity can mediate optimal T-cell activity without self cross-reactivity. Cancer Immunol. Res. 7, 2025\u20132035 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"2923_CR348","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ymthe.2019.10.001","volume":"28","author":"LT Morton","year":"2020","unstructured":"Morton, L. T. et al. Simultaneous Deletion of Endogenous TCR\u03b1\u03b2 for TCR Gene Therapy Creates an Improved and Safe Cellular Therapeutic. Mol. Ther. 28, 64\u201374 (2020).","journal-title":"Mol. Ther."},{"key":"2923_CR349","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.immuni.2016.02.023","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar, O. U. et al. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity 44, 712 (2016).","journal-title":"Immunity"},{"key":"2923_CR350","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581\u2013590 (2015).","journal-title":"Nat. Med."},{"key":"2923_CR351","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","volume":"18","author":"KM Cappell","year":"2021","unstructured":"Cappell, K. M. & Kochenderfer, J. N. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Nat. Rev. Clin. Oncol. 18, 715\u2013727 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2923_CR352","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02371-1","volume":"24","author":"I Can","year":"2025","unstructured":"Can, I. et al. Differential susceptibility and role for senescence in CART cells based on costimulatory domains. Mol. Cancer 24, 172 (2025).","journal-title":"Mol. Cancer"},{"key":"2923_CR353","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl3995","volume":"7","author":"Q Xiao","year":"2022","unstructured":"Xiao, Q. et al. Size-dependent activation of CAR-T cells. Sci. Immunol. 7, eabl3995 (2022).","journal-title":"Sci. Immunol."},{"key":"2923_CR354","doi-asserted-by":"publisher","first-page":"e1253656","DOI":"10.1080\/2162402X.2016.1253656","volume":"5","author":"N Watanabe","year":"2016","unstructured":"Watanabe, N. et al. Fine-tuning the CAR spacer improves T-cell potency. Oncoimmunology 5, e1253656 (2016).","journal-title":"Oncoimmunology"},{"key":"2923_CR355","doi-asserted-by":"crossref","unstructured":"Yang, Y. et al. TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance. Sci. Transl. Med. 9, eaag1209 (2017).","DOI":"10.1126\/scitranslmed.aag1209"},{"key":"2923_CR356","doi-asserted-by":"crossref","unstructured":"Salter, A. I. et al. Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function. Sci. Signal. 14, eabe2606 (2021).","DOI":"10.1126\/scisignal.abe2606"},{"key":"2923_CR357","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41423-020-0470-3","volume":"17","author":"L Wu","year":"2020","unstructured":"Wu, L., Wei, Q., Brzostek, J. & Gascoigne, N. R. J. Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells. Cell Mol. Immunol. 17, 600\u2013612 (2020).","journal-title":"Cell Mol. Immunol."},{"key":"2923_CR358","doi-asserted-by":"publisher","unstructured":"Liseth, O. & Vile, R. The TCR in CAR T cell therapy: use it or lose it? Cancer Gene Ther. https:\/\/doi.org\/10.1038\/s41417-026-01018-7 (2026).","DOI":"10.1038\/s41417-026-01018-7"},{"key":"2923_CR359","doi-asserted-by":"publisher","first-page":"476","DOI":"10.18632\/oncoscience.164","volume":"2","author":"X Zhu","year":"2015","unstructured":"Zhu, X. & Niedermann, G. Rapid and efficient transfer of the T cell aging marker CD57 from glioblastoma stem cells to CAR T cells. Oncoscience 2, 476\u2013482 (2015).","journal-title":"Oncoscience"},{"key":"2923_CR360","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41416-018-0327-z","volume":"120","author":"NA Giraldo","year":"2019","unstructured":"Giraldo, N. A. et al. The clinical role of the TME in solid cancer. Br. J. Cancer 120, 45\u201353 (2019).","journal-title":"Br. J. Cancer"},{"key":"2923_CR361","doi-asserted-by":"publisher","first-page":"101635","DOI":"10.1016\/j.beha.2025.101635","volume":"38","author":"Y Zhu","year":"2025","unstructured":"Zhu, Y., Xu, K. & Wang, Y. Tumor microenvironment in CAR-T cell therapy for lymphoma. Best. Pr. Res Clin. Haematol. 38, 101635 (2025).","journal-title":"Best. Pr. Res Clin. Haematol."},{"key":"2923_CR362","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Ortiz, A. et al. The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression. Cancers 13, 217 (2021).","DOI":"10.3390\/cancers13020217"},{"key":"2923_CR363","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1182\/blood-2012-03-416040","volume":"120","author":"J Ye","year":"2012","unstructured":"Ye, J. et al. Human regulatory T cells induce T-lymphocyte senescence. Blood 120, 2021\u20132031 (2012).","journal-title":"Blood"},{"key":"2923_CR364","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.3389\/fimmu.2020.01371","volume":"11","author":"Y Yang","year":"2020","unstructured":"Yang, Y. et al. Myeloid-Derived Suppressor Cells in Tumors: From Mechanisms to Antigen Specificity and Microenvironmental Regulation. Front Immunol. 11, 1371 (2020).","journal-title":"Front Immunol."},{"key":"2923_CR365","doi-asserted-by":"crossref","unstructured":"Liu, J. et al. MDSCs-derived GPR84 induces CD8+ T cell senescence via p53 activation to suppress the antitumor response. J. Immunother Cancer. 11, e007802 (2023).","DOI":"10.1136\/jitc-2023-007802"},{"key":"2923_CR366","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s00262-023-03594-1","volume":"73","author":"R Towers","year":"2024","unstructured":"Towers, R. et al. Bone marrow-derived mesenchymal stromal cells obstruct AML-targeting CD8+ clonal effector and CAR T-cell function while promoting a senescence-associated phenotype. Cancer Immunol. Immunother. 73, 8 (2024).","journal-title":"Cancer Immunol. Immunother."},{"key":"2923_CR367","doi-asserted-by":"crossref","unstructured":"Yang, R. et al. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade. J. Immunother Cancer. 8, e000610 (2020).","DOI":"10.1136\/jitc-2020-000610"},{"key":"2923_CR368","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1089\/hum.2021.050","volume":"33","author":"Y Qu","year":"2022","unstructured":"Qu, Y. et al. Adenosine Deaminase 1 Overexpression Enhances the Antitumor Efficacy of Chimeric Antigen Receptor-Engineered T Cells. Hum. Gene Ther. 33, 223\u2013236 (2022).","journal-title":"Hum. Gene Ther."},{"key":"2923_CR369","doi-asserted-by":"publisher","first-page":"7176","DOI":"10.1074\/jbc.M109.047423","volume":"285","author":"M Mandapathil","year":"2010","unstructured":"Mandapathil, M. et al. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J. Biol. Chem. 285, 7176\u20137186 (2010).","journal-title":"J. Biol. Chem."},{"key":"2923_CR370","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.4049\/jimmunol.0903647","volume":"184","author":"ST Parish","year":"2010","unstructured":"Parish, S. T. et al. Adenosine deaminase modulation of telomerase activity and replicative senescence in human CD8 T lymphocytes. J. Immunol. 184, 2847\u20132854 (2010).","journal-title":"J. Immunol."},{"key":"2923_CR371","doi-asserted-by":"publisher","first-page":"8489","DOI":"10.2147\/DDDT.S543211","volume":"19","author":"EU Alum","year":"2025","unstructured":"Alum, E. U. et al. Targeting Cellular Senescence for Healthy Aging: Advances in Senolytics and Senomorphics. Drug Des. Devel Ther. 19, 8489\u20138522 (2025).","journal-title":"Drug Des. Devel Ther."},{"key":"2923_CR372","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1111\/febs.16350","volume":"290","author":"L Zhang","year":"2023","unstructured":"Zhang, L. et al. Targeting cellular senescence with senotherapeutics: senolytics and senomorphics. FEBS J. 290, 1362\u20131383 (2023).","journal-title":"FEBS J."},{"key":"2923_CR373","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood.V98.3.597","volume":"98","author":"N Rufer","year":"2001","unstructured":"Rufer, N. et al. Transfer of the human telomerase reverse transcriptase (TERT) gene into T lymphocytes results in extension of replicative potential. Blood 98, 597\u2013603 (2001).","journal-title":"Blood"},{"key":"2923_CR374","doi-asserted-by":"publisher","DOI":"10.1038\/celldisc.2015.40","volume":"1","author":"Y Bai","year":"2015","unstructured":"Bai, Y. et al. Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA. Cell Discov. 1, 15040 (2015).","journal-title":"Cell Discov."},{"key":"2923_CR375","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00018-024-05415-9","volume":"81","author":"S Huang","year":"2024","unstructured":"Huang, S., Lau, C. H., Tin, C. & Lam, R. H. W. Extended replicative lifespan of primary resting T cells by CRISPR\/dCas9-based epigenetic modifiers and transcriptional activators. Cell Mol. Life Sci. 81, 407 (2024).","journal-title":"Cell Mol. Life Sci."},{"key":"2923_CR376","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2023.112130","volume":"174","author":"Y Sugiyama","year":"2023","unstructured":"Sugiyama, Y. et al. A senolytic immunotoxin eliminates p16(INK4a)-positive T cells and ameliorates age-associated phenotype of CD4+ T cells in a surface marker knock-in mouse. Exp. Gerontol. 174, 112130 (2023).","journal-title":"Exp. Gerontol."},{"key":"2923_CR377","doi-asserted-by":"crossref","unstructured":"Legscha, K. J. et al. \u0394133p53\u03b1 enhances metabolic and cellular fitness of TCR-engineered T cells and promotes superior antitumor immunity. J. Immunother Cancer. 9, e001846 (2021).","DOI":"10.1136\/jitc-2020-001846"},{"key":"2923_CR378","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/ncb1928","volume":"11","author":"K Fujita","year":"2009","unstructured":"Fujita, K. et al. p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat. Cell Biol. 11, 1135\u20131142 (2009).","journal-title":"Nat. Cell Biol."},{"key":"2923_CR379","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2317735121","volume":"121","author":"C Roselle","year":"2024","unstructured":"Roselle, C. et al. Enhancing chimeric antigen receptor T cell therapy by modulating the p53 signaling network with \u0394133p53\u03b1. Proc. Natl. Acad. Sci. USA 121, e2317735121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2923_CR380","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202350603","volume":"54","author":"J Jiang","year":"2024","unstructured":"Jiang, J. et al. CD4+CD57+ senescent T cells as promoters of systemic lupus erhthematosus pathogenesis and the therapeutic potential of senolytic BCL-2 inhibitor. Eur. J. Immunol. 54, e2350603 (2024).","journal-title":"Eur. J. Immunol."},{"key":"2923_CR381","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1182\/blood-2002-08-2574","volume":"101","author":"KJ Warrington","year":"2003","unstructured":"Warrington, K. J., Vallejo, A. N., Weyand, C. M. & Goronzy, J. J. CD28 loss in senescent CD4+ T cells: reversal by interleukin-12 stimulation. Blood 101, 3543\u20133549 (2003).","journal-title":"Blood"},{"key":"2923_CR382","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/s10875-010-9449-7","volume":"30","author":"ST Parish","year":"2010","unstructured":"Parish, S. T., Wu, J. E. & Effros, R. B. Sustained CD28 expression delays multiple features of replicative senescence in human CD8 T lymphocytes. J. Clin. Immunol. 30, 798\u2013805 (2010).","journal-title":"J. Clin. Immunol."},{"key":"2923_CR383","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.1158\/1078-0432.CCR-10-3328","volume":"17","author":"Y Zhang","year":"2011","unstructured":"Zhang, Y. et al. Interleukin-7 inhibits tumor-induced CD27-CD28- suppressor T cells: implications for cancer immunotherapy. Clin. Cancer Res 17, 4975\u20134986 (2011).","journal-title":"Clin. Cancer Res"},{"key":"2923_CR384","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cmet.2025.04.008","volume":"37","author":"C Niu","year":"2025","unstructured":"Niu, C. et al. Foxp3 confers long-term efficacy of chimeric antigen receptor-T cells via metabolic reprogramming. Cell Metab. 37, 1426\u20131441.e1427 (2025).","journal-title":"Cell Metab."},{"key":"2923_CR385","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1419","volume":"11","author":"C Zhang","year":"2022","unstructured":"Zhang, C. et al. Autophagic flux restoration of senescent T cells improves antitumor activity of TCR-engineered T cells. Clin. Transl. Immunol. 11, e1419 (2022).","journal-title":"Clin. Transl. Immunol."},{"key":"2923_CR386","doi-asserted-by":"publisher","first-page":"16694","DOI":"10.1021\/jacs.5c05312","volume":"147","author":"XF Bai","year":"2025","unstructured":"Bai, X. F. et al. Click Chemistry-Assisted Rejuvenation of Aging T Cells Sensitizes Aged Mice to Tumor Immunotherapy. J. Am. Chem. Soc. 147, 16694\u201316704 (2025).","journal-title":"J. Am. Chem. Soc."},{"key":"2923_CR387","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-023-01504-7","volume":"16","author":"Y Bulliard","year":"2023","unstructured":"Bulliard, Y. et al. Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy. J. Hematol. Oncol. 16, 108 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"2923_CR388","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40164-024-00535-1","volume":"13","author":"A Van der Vreken","year":"2024","unstructured":"Van der Vreken, A. et al. Fueling CARs: metabolic strategies to enhance CAR T-cell therapy. Exp. Hematol. Oncol. 13, 66 (2024).","journal-title":"Exp. Hematol. Oncol."},{"key":"2923_CR389","doi-asserted-by":"crossref","unstructured":"Tedder, B. & Bhutani, M. Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma. Cells. 14, 1077 (2025).","DOI":"10.3390\/cells14141077"},{"key":"2923_CR390","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41388-020-01501-x","volume":"40","author":"M Poorebrahim","year":"2021","unstructured":"Poorebrahim, M. et al. Counteracting CAR T cell dysfunction. Oncogene 40, 421\u2013435 (2021).","journal-title":"Oncogene"},{"key":"2923_CR391","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101085","volume":"14","author":"X Liu","year":"2021","unstructured":"Liu, X. et al. A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory\/relapsed B cell lymphoma. Transl. Oncol. 14, 101085 (2021).","journal-title":"Transl. Oncol."},{"key":"2923_CR392","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","volume":"56","author":"S Agarwal","year":"2023","unstructured":"Agarwal, S. et al. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells. Immunity 56, 2388\u20132407 e2389 (2023).","journal-title":"Immunity"},{"key":"2923_CR393","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576, 293\u2013300 (2019).","journal-title":"Nature"},{"key":"2923_CR394","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50485-9","volume":"15","author":"S Zuo","year":"2024","unstructured":"Zuo, S. et al. C-JUN overexpressing CAR-T cells in acute myeloid leukemia: preclinical characterization and phase I trial. Nat. Commun. 15, 6155 (2024).","journal-title":"Nat. Commun."},{"key":"2923_CR395","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","volume":"629","author":"JD Chan","year":"2024","unstructured":"Chan, J. D. et al. FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy. Nature 629, 201\u2013210 (2024).","journal-title":"Nature"},{"key":"2923_CR396","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-024-07300-8","volume":"629","author":"AE Doan","year":"2024","unstructured":"Doan, A. E. et al. FOXO1 is a master regulator of memory programming in CAR T cells. Nature 629, 211\u2013218 (2024).","journal-title":"Nature"},{"key":"2923_CR397","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.ccell.2022.11.006","volume":"40","author":"A Smole","year":"2022","unstructured":"Smole, A. et al. Expression of inducible factors reprograms CAR-T cells for enhanced function and safety. Cancer Cell 40, 1470\u20131487.e1477 (2022).","journal-title":"Cancer Cell"},{"key":"2923_CR398","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn7336","volume":"14","author":"IY Jung","year":"2022","unstructured":"Jung, I. Y. et al. BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion. Sci. Transl. Med 14, eabn7336 (2022).","journal-title":"Sci. Transl. Med"},{"key":"2923_CR399","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3830","volume":"4","author":"G Hu","year":"2013","unstructured":"Hu, G. & Chen, J. A genome-wide regulatory network identifies key transcription factors for memory CD8\u207a T-cell development. Nat. Commun. 4, 2830 (2013).","journal-title":"Nat. Commun."},{"key":"2923_CR400","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41590-025-02391-5","volume":"27","author":"TC Chang","year":"2026","unstructured":"Chang, T. C. et al. BACH2 regulates T cell lineage state to enhance CAR T cell function. Nat. Immunol. 27, 413\u2013424 (2026).","journal-title":"Nat. Immunol."},{"key":"2923_CR401","doi-asserted-by":"crossref","unstructured":"Hou, M. et al. Timosaponin AIII enhances CAR-T cell potency and prevents relapse through impairing CAR-Tregs. Nat. Commun. 17, 3045 (2026).","DOI":"10.1038\/s41467-026-70867-5"},{"key":"2923_CR402","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-65897-4","volume":"17","author":"CT Tsai","year":"2026","unstructured":"Tsai, C. T. et al. Enhancing CAR- and TCR-mediated targeting of cancer via an immune synapse-stabilizing receptor. Nat. Commun. 17, 1349 (2026).","journal-title":"Nat. Commun."},{"key":"2923_CR403","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-67745-x","volume":"17","author":"A Itoh-Nakadai","year":"2026","unstructured":"Itoh-Nakadai, A. et al. CXCR4 induces memory formation over exhaustion in CAR-T cells to achieve durable leukemia targeting. Nat. Commun. 17, 101 (2026).","journal-title":"Nat. Commun."},{"key":"2923_CR404","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558, 307\u2013312 (2018).","journal-title":"Nature"},{"key":"2923_CR405","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adp9371","volume":"10","author":"AJ Dimitri","year":"2024","unstructured":"Dimitri, A. J. et al. TET2 regulates early and late transitions in exhausted CD8+ T cell differentiation and limits CAR T cell function. Sci. Adv. 10, eadp9371 (2024).","journal-title":"Sci. Adv."},{"key":"2923_CR406","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41586-022-05692-z","volume":"615","author":"N Jain","year":"2023","unstructured":"Jain, N. et al. TET2 guards against unchecked BATF3-induced CAR T cell expansion. Nature 615, 315\u2013322 (2023).","journal-title":"Nature"},{"key":"2923_CR407","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh0272","volume":"13","author":"B Prinzing","year":"2021","unstructured":"Prinzing, B. et al. Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. Sci. Transl. Med. 13, eabh0272 (2021).","journal-title":"Sci. Transl. Med."},{"key":"2923_CR408","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1158\/2159-8290.CD-22-1319","volume":"14","author":"N Jain","year":"2024","unstructured":"Jain, N. et al. Disruption of SUV39H1-Mediated H3K9 Methylation Sustains CAR T-cell Function. Cancer Discov. 14, 142\u2013157 (2024).","journal-title":"Cancer Discov."},{"key":"2923_CR409","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114065","volume":"43","author":"M Zhu","year":"2024","unstructured":"Zhu, M. et al. Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway. Cell Rep. 43, 114065 (2024).","journal-title":"Cell Rep."},{"key":"2923_CR410","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1158\/1078-0432.CCR-20-2487","volume":"27","author":"X Lei","year":"2021","unstructured":"Lei, X. et al. A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors. Clin. Cancer Res. 27, 3757\u20133771 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2923_CR411","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno, J. N. & Kochenderfer, J. N. Current understanding and management of CAR T cell-associated toxicities. Nat. Rev. Clin. Oncol. 21, 501\u2013521 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2923_CR412","doi-asserted-by":"publisher","DOI":"10.1126\/science.aab4077","volume":"350","author":"CY Wu","year":"2015","unstructured":"Wu, C. Y. et al. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science 350, aab4077 (2015).","journal-title":"Science"},{"key":"2923_CR413","doi-asserted-by":"crossref","unstructured":"Jan, M. et al. Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide. Sci Transl Med. 13, eabb6295 (2021).","DOI":"10.1126\/scitranslmed.abb6295"},{"key":"2923_CR414","doi-asserted-by":"crossref","unstructured":"Weber, E. W. et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science. 372, eaba1786 (2021).","DOI":"10.1126\/science.aba1786"},{"key":"2923_CR415","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","volume":"3","author":"EW Weber","year":"2019","unstructured":"Weber, E. W. et al. Pharmacologic control of CAR-T cell function using dasatinib. Blood Adv. 3, 711\u2013717 (2019).","journal-title":"Blood Adv."},{"key":"2923_CR416","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature 543, 113\u2013117 (2017).","journal-title":"Nature"},{"key":"2923_CR417","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1016\/j.ymthe.2021.05.006","volume":"29","author":"B Webster","year":"2021","unstructured":"Webster, B. et al. Self-driving armored CAR-T cells overcome a suppressive milieu and eradicate CD19(+) Raji lymphoma in preclinical models. Mol. Ther. 29, 2691\u20132706 (2021).","journal-title":"Mol. Ther."},{"key":"2923_CR418","doi-asserted-by":"crossref","unstructured":"Choe, J. H. et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 13, eabe7378 (2021).","DOI":"10.1126\/scitranslmed.abe7378"},{"key":"2923_CR419","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","volume":"167","author":"KT Roybal","year":"2016","unstructured":"Roybal, K. T. et al. Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell 167, 419\u2013432 e416 (2016).","journal-title":"Cell"},{"key":"2923_CR420","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41570-025-00768-6","volume":"9","author":"EL Adams","year":"2025","unstructured":"Adams, E. L. et al. Small-molecule control of CAR T cells. Nat. Rev. Chem. 9, 809\u2013825 (2025).","journal-title":"Nat. Rev. Chem."},{"key":"2923_CR421","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","volume":"6","author":"S Ghassemi","year":"2022","unstructured":"Ghassemi, S. et al. Rapid manufacturing of non-activated potent CAR T cells. Nat. Biomed. Eng. 6, 118\u2013128 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"2923_CR422","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00694-6","volume":"12","author":"J Yang","year":"2022","unstructured":"Yang, J. et al. Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study. Blood Cancer J. 12, 104 (2022).","journal-title":"Blood Cancer J."},{"key":"2923_CR423","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.3324\/haematol.2022.282005","volume":"108","author":"P Harrington","year":"2023","unstructured":"Harrington, P. et al. Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia. Haematologica 108, 1555\u20131566 (2023).","journal-title":"Haematologica"},{"key":"2923_CR424","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/8394960","volume":"2016","author":"H Saito","year":"2016","unstructured":"Saito, H. et al. Reprogramming of Melanoma Tumor-Infiltrating Lymphocytes to Induced Pluripotent Stem Cells. Stem Cells Int. 2016, 8394960 (2016).","journal-title":"Stem Cells Int."},{"key":"2923_CR425","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.stem.2012.11.002","volume":"12","author":"T Nishimura","year":"2013","unstructured":"Nishimura, T. et al. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell 12, 114\u2013126 (2013).","journal-title":"Cell Stem Cell"},{"key":"2923_CR426","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1158\/2767-9764.CRC-22-0265","volume":"3","author":"SMR Islam","year":"2023","unstructured":"Islam, S. M. R. et al. Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells. Cancer Res. Commun. 3, 917\u2013932 (2023).","journal-title":"Cancer Res. Commun."},{"key":"2923_CR427","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/exd.14686","volume":"32","author":"M Itoh","year":"2023","unstructured":"Itoh, M. et al. Generation of induced pluripotent stem cell (iPSC) from NY-ESO-I-specific cytotoxic T cells isolated from the melanoma patient with minor HLAs: The practical pilot study for the adoptive immunotherapy for melanoma using iPSC technology. Exp. Dermatol. 32, 126\u2013134 (2023).","journal-title":"Exp. Dermatol."},{"key":"2923_CR428","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1158\/2326-6066.CIR-18-0243","volume":"6","author":"CD Zahm","year":"2018","unstructured":"Zahm, C. D. et al. TLR Stimulation during T-cell Activation Lowers PD-1 Expression on CD8+ T cells. Cancer Immunol. Res. 6, 1364\u20131374 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"2923_CR429","doi-asserted-by":"publisher","first-page":"e1237327","DOI":"10.1080\/2162402X.2016.1237327","volume":"5","author":"J Weng","year":"2016","unstructured":"Weng, J. et al. IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay. Oncoimmunology 5, e1237327 (2016).","journal-title":"Oncoimmunology"},{"key":"2923_CR430","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1182\/blood-2012-05-431718","volume":"121","author":"N Cieri","year":"2013","unstructured":"Cieri, N. et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 121, 573\u2013584 (2013).","journal-title":"Blood"},{"key":"2923_CR431","doi-asserted-by":"publisher","first-page":"4807853","DOI":"10.1155\/2017\/4807853","volume":"2017","author":"V Nguyen","year":"2017","unstructured":"Nguyen, V., Mendelsohn, A. & Larrick, J. W. Interleukin-7 and Immunosenescence. J. Immunol. Res. 2017, 4807853 (2017).","journal-title":"J. Immunol. Res."},{"key":"2923_CR432","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1116328","volume":"13","author":"S Yunger","year":"2023","unstructured":"Yunger, S. et al. Modulating the proliferative and cytotoxic properties of patient-derived TIL by a synthetic immune niche of immobilized CCL21 and ICAM1. Front. Oncol. 13, 1116328 (2023).","journal-title":"Front. Oncol."},{"key":"2923_CR433","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ccell.2024.01.002","volume":"42","author":"DD Klysz","year":"2024","unstructured":"Klysz, D. D. et al. Inosine induces stemness features in CAR-T cells and enhances potency. Cancer Cell 42, 266\u2013282.e268 (2024).","journal-title":"Cancer Cell"},{"key":"2923_CR434","doi-asserted-by":"crossref","unstructured":"Arcangeli, S. et al. CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. J. Clin. Invest. 132, e150807 (2022).","DOI":"10.1172\/JCI150807"},{"key":"2923_CR435","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.3389\/fimmu.2020.01217","volume":"11","author":"S Arcangeli","year":"2020","unstructured":"Arcangeli, S. et al. Next-Generation Manufacturing Protocols Enriching T(SCM) CAR T cells can overcome disease-specific T cell defects in cancer patients. Front. Immunol. 11, 1217 (2020).","journal-title":"Front. Immunol."},{"key":"2923_CR436","doi-asserted-by":"publisher","first-page":"102377","DOI":"10.1016\/j.eclinm.2023.102377","volume":"67","author":"Y Luo","year":"2024","unstructured":"Luo, Y. et al. Donor-derived Anti-CD19 CAR T cells GC007g for relapsed or refractory B-cell acute lymphoblastic leukemia after allogeneic HSCT: a phase 1 trial. EClinicalMedicine 67, 102377 (2024).","journal-title":"EClinicalMedicine"},{"key":"2923_CR437","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-65267-0","volume":"16","author":"H Tseng","year":"2025","unstructured":"Tseng, H. et al. T(SCM)-predominant allogeneic anti-BCMA CAR-T therapy for relapsed\/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial. Nat. Commun. 16, 10050 (2025).","journal-title":"Nat. Commun."},{"key":"2923_CR438","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30896-2","volume":"13","author":"S Jo","year":"2022","unstructured":"Jo, S. et al. Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing. Nat. Commun. 13, 3453 (2022).","journal-title":"Nat. Commun."},{"key":"2923_CR439","doi-asserted-by":"crossref","unstructured":"Qasim, W. et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci. Transl. Med. 9, eaaj2013 (2017).","DOI":"10.1126\/scitranslmed.aaj2013"},{"key":"2923_CR440","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/cr.2016.142","volume":"27","author":"X Liu","year":"2017","unstructured":"Liu, X. et al. CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells. Cell Res. 27, 154\u2013157 (2017).","journal-title":"Cell Res."},{"key":"2923_CR441","doi-asserted-by":"crossref","unstructured":"Wang, M. et al. Co-Delivery of Multiple RNAs via Lipid Nanoparticles Enables Precise Gene Editing of CAR-T Cells. Adv. Healthc. Mater. 15, e01475 (2025).","DOI":"10.1002\/adhm.202501475"},{"key":"2923_CR442","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1016\/j.ymthe.2022.06.006","volume":"30","author":"J Tipanee","year":"2022","unstructured":"Tipanee, J. et al. Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy. Mol. Ther. 30, 3155\u20133175 (2022).","journal-title":"Mol. Ther."},{"key":"2923_CR443","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1158\/2326-6066.CIR-18-0508","volume":"8","author":"Y Kagoya","year":"2020","unstructured":"Kagoya, Y. et al. Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy. Cancer Immunol. Res. 8, 926\u2013936 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"2923_CR444","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1182\/blood-2013-03-478255","volume":"122","author":"H Torikai","year":"2013","unstructured":"Torikai, H. et al. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood 122, 1341\u20131349 (2013).","journal-title":"Blood"},{"key":"2923_CR445","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00262-023-03586-1","volume":"73","author":"X Chen","year":"2024","unstructured":"Chen, X. et al. Allogeneic CAR-T cells with of HLA-A\/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies. Cancer Immunol. Immunother. 73, 13 (2024).","journal-title":"Cancer Immunol. Immunother."},{"key":"2923_CR446","doi-asserted-by":"publisher","first-page":"e833","DOI":"10.1016\/S2352-3026(22)00245-9","volume":"9","author":"R Benjamin","year":"2022","unstructured":"Benjamin, R. et al. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. Lancet Haematol. 9, e833\u2013e843 (2022).","journal-title":"Lancet Haematol."},{"key":"2923_CR447","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","volume":"23","author":"J Ren","year":"2017","unstructured":"Ren, J. et al. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition. Clin. Cancer Res. 23, 2255\u20132266 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2923_CR448","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s40425-019-0806-7","volume":"7","author":"BD Choi","year":"2019","unstructured":"Choi, B. D. et al. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. J. Immunother. Cancer 7, 304 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"2923_CR449","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-68112-6","volume":"17","author":"X Li","year":"2026","unstructured":"Li, X. et al. Intrathecal CRISPR-edited allogeneic IL-13R\u03b12 CAR T Cells for recurrent high-grade Glioma: preclinical characterization and phase I trial. Nat. Commun. 17, 1362 (2026).","journal-title":"Nat. Commun."},{"key":"2923_CR450","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2427216122","volume":"122","author":"NW Engel","year":"2025","unstructured":"Engel, N. W. et al. Quadruple adenine base-edited allogeneic CAR T cells outperform CRISPR\/Cas9 nuclease-engineered T cells. Proc. Natl. Acad. Sci. USA 122, e2427216122 (2025).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2923_CR451","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1056\/NEJMoa2505478","volume":"394","author":"R Chiesa","year":"2026","unstructured":"Chiesa, R. et al. Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia. N. Engl. J. Med. 394, 152\u2013165 (2026).","journal-title":"N. Engl. J. Med."},{"key":"2923_CR452","doi-asserted-by":"publisher","first-page":"1139482","DOI":"10.3389\/fimmu.2023.1139482","volume":"14","author":"T Yu","year":"2023","unstructured":"Yu, T. et al. Cord blood-derived CD19-specific chimeric antigen receptor T cells: an off-the-shelf promising therapeutic option for treatment of diffuse large B-cell lymphoma. Front. Immunol. 14, 1139482 (2023).","journal-title":"Front. Immunol."},{"key":"2923_CR453","first-page":"3941","volume":"109","author":"C Georgiadis","year":"2024","unstructured":"Georgiadis, C. et al. Umbilical cord blood T cells can be isolated and enriched by CD62L selection for use in \u2018off the shelf\u2019 chimeric antigen receptor T-cell therapies to widen transplant options. Haematologica 109, 3941\u20133951 (2024).","journal-title":"Haematologica"},{"key":"2923_CR454","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.stem.2025.03.006","volume":"32","author":"R Jing","year":"2025","unstructured":"Jing, R. et al. EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity. Cell Stem Cell 32, 670 (2025).","journal-title":"Cell Stem Cell"},{"key":"2923_CR455","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nbt.2678","volume":"31","author":"M Themeli","year":"2013","unstructured":"Themeli, M. et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat. Biotechnol. 31, 928\u2013933 (2013).","journal-title":"Nat. Biotechnol."},{"key":"2923_CR456","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1182\/blood.2023020528","volume":"143","author":"J Bae","year":"2024","unstructured":"Bae, J. et al. Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8\u03b1\u03b2+ T cells targeting multiple myeloma. Blood 143, 895\u2013911 (2024).","journal-title":"Blood"},{"key":"2923_CR457","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.stem.2019.02.005","volume":"24","author":"H Xu","year":"2019","unstructured":"Xu, H. et al. Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility. Cell Stem Cell 24, 566\u2013578.e567 (2019).","journal-title":"Cell Stem Cell"},{"key":"2923_CR458","doi-asserted-by":"crossref","unstructured":"Muroyama, Y. & Wherry, E. J. Memory T-Cell Heterogeneity and Terminology. Cold Spring Harb. Perspect. Biol. 13, a037929 (2021).","DOI":"10.1101\/cshperspect.a037929"},{"key":"2923_CR459","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/(SICI)1521-1878(199906)21:6<519::AID-BIES8>3.0.CO;2-U","volume":"21","author":"R Aspinall","year":"1999","unstructured":"Aspinall, R. Does the immune system of a mouse age faster than the immune system of a human? Bioessays 21, 519\u2013524 (1999).","journal-title":"Bioessays"},{"key":"2923_CR460","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0047-6374(00)00198-6","volume":"121","author":"AN Akbar","year":"2000","unstructured":"Akbar, A. N., Soares, M. V., Plunkett, F. J. & Salmon, M. Differential regulation of CD8+ T cell senescence in mice and men. Mech. Ageing Dev. 121, 69\u201376 (2000).","journal-title":"Mech. Ageing Dev."},{"key":"2923_CR461","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1182\/blood-2002-07-2015","volume":"102","author":"A Roth","year":"2003","unstructured":"Roth, A. et al. Telomerase levels control the lifespan of human T lymphocytes. Blood 102, 849\u2013857 (2003).","journal-title":"Blood"},{"key":"2923_CR462","doi-asserted-by":"publisher","first-page":"1338680","DOI":"10.3389\/fimmu.2024.1338680","volume":"15","author":"M Huang","year":"2024","unstructured":"Huang, M. et al. T cell senescence: a new perspective on immunotherapy in lung cancer. Front. Immunol. 15, 1338680 (2024).","journal-title":"Front. Immunol."},{"key":"2923_CR463","doi-asserted-by":"publisher","first-page":"175","DOI":"10.5415\/apallergy.0000000000000128","volume":"13","author":"X Meng","year":"2023","unstructured":"Meng, X. et al. Immunological mechanisms of tolerance: Central, peripheral and the role of T and B cells. Asia Pac. Allergy 13, 175\u2013186 (2023).","journal-title":"Asia Pac. Allergy"},{"key":"2923_CR464","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/imm.13575","volume":"167","author":"F Li","year":"2022","unstructured":"Li, F. et al. Metabolic plasticity and regulation of T cell exhaustion. Immunology 167, 482\u2013494 (2022).","journal-title":"Immunology"},{"key":"2923_CR465","doi-asserted-by":"publisher","first-page":"101808","DOI":"10.1016\/j.smim.2023.101808","volume":"69","author":"JI Escrig-Larena","year":"2023","unstructured":"Escrig-Larena, J. I., Delgado-Pulido, S. & Mittelbrunn, M. Mitochondria during T cell aging. Semin. Immunol. 69, 101808 (2023).","journal-title":"Semin. Immunol."},{"key":"2923_CR466","doi-asserted-by":"crossref","unstructured":"Ouyang, W. et al. PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion. J. Immunother Cancer. 12, e008429 (2024).","DOI":"10.1136\/jitc-2023-008429"},{"key":"2923_CR467","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj3510","volume":"378","author":"M Al-Habsi","year":"2022","unstructured":"Al-Habsi, M. et al. Spermidine activates mitochondrial trifunctional protein and improves antitumor immunity in mice. Science 378, eabj3510 (2022).","journal-title":"Science"},{"key":"2923_CR468","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12979-023-00394-0","volume":"20","author":"J Yang","year":"2023","unstructured":"Yang, J. et al. The effect of metformin on senescence of T lymphocytes. Immun. Ageing 20, 73 (2023).","journal-title":"Immun. Ageing"},{"key":"2923_CR469","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.cmet.2020.04.015","volume":"32","author":"LP Bharath","year":"2020","unstructured":"Bharath, L. P. et al. Metformin Enhances Autophagy and Normalizes Mitochondrial Function to Alleviate Aging-Associated Inflammation. Cell Metab. 32, 44\u201355.e46 (2020).","journal-title":"Cell Metab."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02923-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02923-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02923-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:01:50Z","timestamp":1788390110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02923-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":469,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2923"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02923-x","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"3 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"362"}}